https://trial.medpath.com/news/phase-iii-trybeca-1-trial-shows-eryaspase-fails-to-improve-survival-in-advanced-pancreatic-cancer 2025-11-12T21:21:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-iii-trybeca-1-trial-shows-eryaspase-fails-to-improve-survival-in-advanced-pancreatic-cancer 2025-11-12T21:21:30+00:00 hourly 0.9 https://trial.medpath.com/news/durvascc-trial-evaluates-durvalumab-chemotherapy-combination-for-rare-extrapulmonary-small-cell-carcinoma 2025-11-12T21:20:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/durvascc-trial-evaluates-durvalumab-chemotherapy-combination-for-rare-extrapulmonary-small-cell-carcinoma 2025-11-12T21:20:56+00:00 hourly 0.9 https://trial.medpath.com/news/single-dose-malaria-treatment-achieves-93-cure-rate-in-phase-3-trial-matching-standard-multi-day-therapy 2025-11-12T21:19:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/single-dose-malaria-treatment-achieves-93-cure-rate-in-phase-3-trial-matching-standard-multi-day-therapy 2025-11-12T21:19:46+00:00 hourly 0.9 https://trial.medpath.com/news/neurogene-advances-ngn-401-gene-therapy-for-rett-syndrome-with-positive-interim-data-and-registrational-trial-progress 2025-11-12T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurogene-advances-ngn-401-gene-therapy-for-rett-syndrome-with-positive-interim-data-and-registrational-trial-progress 2025-11-12T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/aprea-therapeutics-reports-promising-early-clinical-data-for-dna-damage-response-inhibitors 2025-11-12T17:30:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aprea-therapeutics-reports-promising-early-clinical-data-for-dna-damage-response-inhibitors 2025-11-12T17:30:17+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-drops-cvs-drug-plan-for-employees-following-weight-loss-drug-coverage-dispute 2025-11-12T17:30:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-drops-cvs-drug-plan-for-employees-following-weight-loss-drug-coverage-dispute 2025-11-12T17:30:12+00:00 hourly 0.9 https://trial.medpath.com/news/sequential-car-t-cell-therapy-and-autologous-stem-cell-transplant-shows-97-survival-rate-in-ph-negative-b-all 2025-11-12T17:24:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sequential-car-t-cell-therapy-and-autologous-stem-cell-transplant-shows-97-survival-rate-in-ph-negative-b-all 2025-11-12T17:24:54+00:00 hourly 0.9 https://trial.medpath.com/news/vietnam-approves-russian-pembrolizumab-biosimilar-for-cancer-treatment 2025-11-12T17:24:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vietnam-approves-russian-pembrolizumab-biosimilar-for-cancer-treatment 2025-11-12T17:24:44+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-evidence-shows-potential-survival-advantage-for-apalutamide-over-abiraterone-in-metastatic-prostate-cancer 2025-11-12T17:23:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-evidence-shows-potential-survival-advantage-for-apalutamide-over-abiraterone-in-metastatic-prostate-cancer 2025-11-12T17:23:40+00:00 hourly 0.9 https://trial.medpath.com/news/dyno-therapeutics-and-trisk-bio-form-strategic-manufacturing-partnership-to-accelerate-gene-therapy-development 2025-11-12T17:22:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dyno-therapeutics-and-trisk-bio-form-strategic-manufacturing-partnership-to-accelerate-gene-therapy-development 2025-11-12T17:22:45+00:00 hourly 0.9 https://trial.medpath.com/news/eirgenix-secures-152m-licensing-deal-with-sandoz-for-her2-positive-breast-cancer-biosimilar 2025-11-12T17:21:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eirgenix-secures-152m-licensing-deal-with-sandoz-for-her2-positive-breast-cancer-biosimilar 2025-11-12T17:21:52+00:00 hourly 0.9 https://trial.medpath.com/news/xoma-royalty-reports-strong-q3-2025-results-with-multiple-strategic-acquisitions-and-key-pipeline-milestones 2025-11-12T17:21:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xoma-royalty-reports-strong-q3-2025-results-with-multiple-strategic-acquisitions-and-key-pipeline-milestones 2025-11-12T17:21:35+00:00 hourly 0.9 https://trial.medpath.com/news/seed-therapeutics-receives-china-nmpa-clearance-for-st-01156-molecular-glue-degrader-in-rare-cancer-trial 2025-11-12T17:21:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seed-therapeutics-receives-china-nmpa-clearance-for-st-01156-molecular-glue-degrader-in-rare-cancer-trial 2025-11-12T17:21:30+00:00 hourly 0.9 https://trial.medpath.com/news/remedy-plan-therapeutics-achieves-breakthrough-with-first-safe-nampt-inhibitor-rpt1g-for-blood-cancers 2025-11-12T17:21:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/remedy-plan-therapeutics-achieves-breakthrough-with-first-safe-nampt-inhibitor-rpt1g-for-blood-cancers 2025-11-12T17:21:21+00:00 hourly 0.9 https://trial.medpath.com/news/indivi-secures-chf-15-million-to-advance-alzheimer-s-biomarker-discovery-platform 2025-11-12T17:21:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indivi-secures-chf-15-million-to-advance-alzheimer-s-biomarker-discovery-platform 2025-11-12T17:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/bostongene-and-kyoto-university-partner-to-develop-ai-powered-biomarkers-for-esophageal-cancer-treatment 2025-11-12T17:20:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bostongene-and-kyoto-university-partner-to-develop-ai-powered-biomarkers-for-esophageal-cancer-treatment 2025-11-12T17:20:55+00:00 hourly 0.9 https://trial.medpath.com/news/pepgen-secures-u-s-patent-for-pgn-edodm1-advancing-myotonic-dystrophy-type-1-treatment 2025-11-12T17:20:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pepgen-secures-u-s-patent-for-pgn-edodm1-advancing-myotonic-dystrophy-type-1-treatment 2025-11-12T17:20:10+00:00 hourly 0.9 https://trial.medpath.com/news/elite-pharmaceuticals-secures-fda-approval-for-generic-ropinirole-extended-release-tablets-for-parkinson-s-disease 2025-11-12T17:19:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elite-pharmaceuticals-secures-fda-approval-for-generic-ropinirole-extended-release-tablets-for-parkinson-s-disease 2025-11-12T17:19:26+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accelerated-approval-pathway-under-scrutiny-as-sarepta-seeks-traditional-approval-despite-failed-dmd-trial 2025-11-12T17:18:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accelerated-approval-pathway-under-scrutiny-as-sarepta-seeks-traditional-approval-despite-failed-dmd-trial 2025-11-12T17:18:44+00:00 hourly 0.9 https://trial.medpath.com/news/fgf18-emerges-as-promising-therapeutic-target-for-post-traumatic-osteoarthritis-through-foxn2-pathway 2025-11-12T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fgf18-emerges-as-promising-therapeutic-target-for-post-traumatic-osteoarthritis-through-foxn2-pathway 2025-11-12T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/longeveron-secures-u-s-patent-for-stem-cell-treatment-of-aging-related-frailty 2025-11-12T14:11:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/longeveron-secures-u-s-patent-for-stem-cell-treatment-of-aging-related-frailty 2025-11-12T14:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/apellis-syfovre-shows-sustained-efficacy-in-five-year-geographic-atrophy-study-delaying-disease-progression-by-1-5-years 2025-11-12T13:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apellis-syfovre-shows-sustained-efficacy-in-five-year-geographic-atrophy-study-delaying-disease-progression-by-1-5-years 2025-11-12T13:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/ovid-therapeutics-advances-ov329-to-phase-2-following-positive-safety-results-in-drug-resistant-epilepsy-program 2025-11-12T13:24:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ovid-therapeutics-advances-ov329-to-phase-2-following-positive-safety-results-in-drug-resistant-epilepsy-program 2025-11-12T13:24:39+00:00 hourly 0.9 https://trial.medpath.com/news/india-launches-first-car-t-manufacturing-training-program-to-build-cell-and-gene-therapy-expertise 2025-11-12T13:24:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-launches-first-car-t-manufacturing-training-program-to-build-cell-and-gene-therapy-expertise 2025-11-12T13:24:11+00:00 hourly 0.9 https://trial.medpath.com/news/adocia-files-patent-for-adoxlong-platform-to-extend-peptide-therapy-duration-to-monthly-injections 2025-11-12T13:22:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adocia-files-patent-for-adoxlong-platform-to-extend-peptide-therapy-duration-to-monthly-injections 2025-11-12T13:22:15+00:00 hourly 0.9 https://trial.medpath.com/news/nanoform-receives-european-commercial-cgmp-license-advances-multiple-nanoformulated-drug-programs 2025-11-12T13:20:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanoform-receives-european-commercial-cgmp-license-advances-multiple-nanoformulated-drug-programs 2025-11-12T13:20:44+00:00 hourly 0.9 https://trial.medpath.com/news/nuformix-receives-fda-clarification-request-for-orphan-drug-designation-of-tranilast-in-idiopathic-pulmonary-fibrosis 2025-11-12T13:20:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuformix-receives-fda-clarification-request-for-orphan-drug-designation-of-tranilast-in-idiopathic-pulmonary-fibrosis 2025-11-12T13:20:10+00:00 hourly 0.9 https://trial.medpath.com/news/mhra-approves-betaglue-therapeutics-yntradose-clinical-trial-for-unresectable-pancreatic-cancer 2025-11-12T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mhra-approves-betaglue-therapeutics-yntradose-clinical-trial-for-unresectable-pancreatic-cancer 2025-11-12T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/abeona-therapeutics-advances-zevaskyn-gene-therapy-commercialization-for-rare-skin-disease 2025-11-12T11:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abeona-therapeutics-advances-zevaskyn-gene-therapy-commercialization-for-rare-skin-disease 2025-11-12T11:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/australian-blood-test-shows-promise-for-personalizing-parp-inhibitor-therapy-in-ovarian-cancer 2025-11-12T09:21:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australian-blood-test-shows-promise-for-personalizing-parp-inhibitor-therapy-in-ovarian-cancer 2025-11-12T09:21:26+00:00 hourly 0.9 https://trial.medpath.com/news/dbv-technologies-completes-patient-enrollment-in-pivotal-vitesse-phase-3-trial-for-peanut-allergy-patch 2025-11-12T09:21:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dbv-technologies-completes-patient-enrollment-in-pivotal-vitesse-phase-3-trial-for-peanut-allergy-patch 2025-11-12T09:21:18+00:00 hourly 0.9 https://trial.medpath.com/news/indian-pharma-companies-win-major-generic-drug-supply-contracts-in-china-s-healthcare-market 2025-11-12T09:20:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indian-pharma-companies-win-major-generic-drug-supply-contracts-in-china-s-healthcare-market 2025-11-12T09:20:18+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-magstim-magnetic-stimulation-device-for-chronic-pain-treatment 2025-11-12T08:22:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-magstim-magnetic-stimulation-device-for-chronic-pain-treatment 2025-11-12T08:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/cogent-biosciences-raises-475-3-million-to-advance-bezuclastinib-for-systemic-mastocytosis 2025-11-12T06:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cogent-biosciences-raises-475-3-million-to-advance-bezuclastinib-for-systemic-mastocytosis 2025-11-12T06:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/earlier-hepatitis-c-cure-assessment-shows-promise-for-high-risk-populations 2025-11-12T05:21:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/earlier-hepatitis-c-cure-assessment-shows-promise-for-high-risk-populations 2025-11-12T05:21:13+00:00 hourly 0.9 https://trial.medpath.com/news/abl-bio-secures-2-6-billion-deal-and-180-million-strategic-investment-from-eli-lilly-for-grabbody-platform 2025-11-12T05:21:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abl-bio-secures-2-6-billion-deal-and-180-million-strategic-investment-from-eli-lilly-for-grabbody-platform 2025-11-12T05:21:08+00:00 hourly 0.9 https://trial.medpath.com/news/pathkey-and-armstrong-clinical-partner-to-enhance-early-phase-trial-success-through-ai-powered-design 2025-11-12T05:20:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pathkey-and-armstrong-clinical-partner-to-enhance-early-phase-trial-success-through-ai-powered-design 2025-11-12T05:20:31+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-shows-equivalent-survival-outcomes-for-abiraterone-and-enzalutamide-in-veterans-with-metastatic-prostate-cancer 2025-11-12T05:20:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-shows-equivalent-survival-outcomes-for-abiraterone-and-enzalutamide-in-veterans-with-metastatic-prostate-cancer 2025-11-12T05:20:23+00:00 hourly 0.9 https://trial.medpath.com/news/medley-therapeutics-advances-first-in-human-gene-therapy-trial-for-heart-regeneration-after-safety-milestone 2025-11-12T05:20:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medley-therapeutics-advances-first-in-human-gene-therapy-trial-for-heart-regeneration-after-safety-milestone 2025-11-12T05:20:07+00:00 hourly 0.9 https://trial.medpath.com/news/dyno-therapeutics-unveils-ai-engineered-aav-vector-dyno-bn8-for-muscle-gene-therapy-with-25-fold-dose-reduction 2025-11-12T05:20:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dyno-therapeutics-unveils-ai-engineered-aav-vector-dyno-bn8-for-muscle-gene-therapy-with-25-fold-dose-reduction 2025-11-12T05:20:04+00:00 hourly 0.9 https://trial.medpath.com/news/lecanemab-clears-alzheimer-s-plaques-but-fails-to-restore-brain-s-waste-clearance-system 2025-11-12T01:24:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lecanemab-clears-alzheimer-s-plaques-but-fails-to-restore-brain-s-waste-clearance-system 2025-11-12T01:24:08+00:00 hourly 0.9 https://trial.medpath.com/news/metagenomi-advances-mgx-001-hemophilia-a-gene-therapy-with-curative-activity-in-primates 2025-11-12T01:23:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metagenomi-advances-mgx-001-hemophilia-a-gene-therapy-with-curative-activity-in-primates 2025-11-12T01:23:19+00:00 hourly 0.9 https://trial.medpath.com/news/curegene-s-cg-0416-shows-superior-fat-loss-while-preserving-muscle-in-preclinical-obesity-studies 2025-11-12T01:23:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curegene-s-cg-0416-shows-superior-fat-loss-while-preserving-muscle-in-preclinical-obesity-studies 2025-11-12T01:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/university-hospital-tubingen-launches-depeca-1-trial-testing-enfortumab-vedotin-avelumab-combination-for-advanced-penile-cancer 2025-11-12T01:22:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-hospital-tubingen-launches-depeca-1-trial-testing-enfortumab-vedotin-avelumab-combination-for-advanced-penile-cancer 2025-11-12T01:22:33+00:00 hourly 0.9 https://trial.medpath.com/news/metagenomi-s-mgx-001-gene-therapy-achieves-curative-factor-viii-levels-in-hemophilia-a-preclinical-study 2025-11-12T01:21:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metagenomi-s-mgx-001-gene-therapy-achieves-curative-factor-viii-levels-in-hemophilia-a-preclinical-study 2025-11-12T01:21:52+00:00 hourly 0.9 https://trial.medpath.com/news/fda-recalls-generic-vyvanse-due-to-failed-dissolution-tests-affecting-therapeutic-efficacy 2025-11-12T01:21:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-recalls-generic-vyvanse-due-to-failed-dissolution-tests-affecting-therapeutic-efficacy 2025-11-12T01:21:32+00:00 hourly 0.9 https://trial.medpath.com/news/sellas-life-sciences-reports-promising-phase-2-results-for-sls009-in-venetoclax-resistant-aml-at-ash-2025 2025-11-11T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sellas-life-sciences-reports-promising-phase-2-results-for-sls009-in-venetoclax-resistant-aml-at-ash-2025 2025-11-11T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/usa-rare-earth-completes-strategic-acquisition-of-less-common-metals-secures-european-rare-earth-supply-chain 2025-11-11T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/usa-rare-earth-completes-strategic-acquisition-of-less-common-metals-secures-european-rare-earth-supply-chain 2025-11-11T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/adia-med-receives-irb-approval-for-autism-clinical-trial-combining-stem-cells-with-glutathione 2025-11-11T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adia-med-receives-irb-approval-for-autism-clinical-trial-combining-stem-cells-with-glutathione 2025-11-11T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/longeveron-secures-canadian-patent-for-stem-cell-therapy-targeting-aging-related-frailty-and-heart-disease 2025-11-11T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/longeveron-secures-canadian-patent-for-stem-cell-therapy-targeting-aging-related-frailty-and-heart-disease 2025-11-11T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/visby-medical-expands-access-to-first-fda-authorized-at-home-pcr-test-for-stis-through-quest-and-labcorp-partnerships 2025-11-11T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/visby-medical-expands-access-to-first-fda-authorized-at-home-pcr-test-for-stis-through-quest-and-labcorp-partnerships 2025-11-11T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/cnipa-invalidates-tofacitinib-sustained-release-patent-over-lack-of-inventive-step 2025-11-11T21:23:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cnipa-invalidates-tofacitinib-sustained-release-patent-over-lack-of-inventive-step 2025-11-11T21:23:46+00:00 hourly 0.9 https://trial.medpath.com/news/tel-aviv-university-researchers-discover-rna-based-gene-therapy-that-reverses-als-nerve-damage 2025-11-11T21:22:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tel-aviv-university-researchers-discover-rna-based-gene-therapy-that-reverses-als-nerve-damage 2025-11-11T21:22:17+00:00 hourly 0.9 https://trial.medpath.com/news/neuphoria-therapeutics-receives-5-20-per-share-acquisition-offer-from-lynx1-master-fund-following-phase-iii-trial-failure 2025-11-11T21:21:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuphoria-therapeutics-receives-5-20-per-share-acquisition-offer-from-lynx1-master-fund-following-phase-iii-trial-failure 2025-11-11T21:21:56+00:00 hourly 0.9 https://trial.medpath.com/news/engene-s-gene-therapy-achieves-63-complete-response-rate-in-pivotal-bladder-cancer-trial 2025-11-11T21:21:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/engene-s-gene-therapy-achieves-63-complete-response-rate-in-pivotal-bladder-cancer-trial 2025-11-11T21:21:42+00:00 hourly 0.9 https://trial.medpath.com/news/quoin-pharmaceuticals-surges-on-fda-orphan-drug-designation-for-rare-skin-disorder-treatment 2025-11-11T21:20:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quoin-pharmaceuticals-surges-on-fda-orphan-drug-designation-for-rare-skin-disorder-treatment 2025-11-11T21:20:27+00:00 hourly 0.9 https://trial.medpath.com/news/new-report-analyzes-biotechnology-licensing-trends-and-deal-structures-from-2020-2025 2025-11-11T21:20:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-report-analyzes-biotechnology-licensing-trends-and-deal-structures-from-2020-2025 2025-11-11T21:20:05+00:00 hourly 0.9 https://trial.medpath.com/news/south-africa-launches-first-domestically-developed-cholera-vaccine-trials 2025-11-11T21:17:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/south-africa-launches-first-domestically-developed-cholera-vaccine-trials 2025-11-11T21:17:56+00:00 hourly 0.9 https://trial.medpath.com/news/coramitug-phase-2-data-published-in-circulation-as-novo-nordisk-advances-phase-3-cleopattra-trial-for-attr-cardiomyopathy 2025-11-11T17:26:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/coramitug-phase-2-data-published-in-circulation-as-novo-nordisk-advances-phase-3-cleopattra-trial-for-attr-cardiomyopathy 2025-11-11T17:26:29+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-drug-venetoclax-shows-100-efficacy-in-preventing-als-progression-in-preclinical-study 2025-11-11T17:26:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-drug-venetoclax-shows-100-efficacy-in-preventing-als-progression-in-preclinical-study 2025-11-11T17:26:22+00:00 hourly 0.9 https://trial.medpath.com/news/irhythm-s-zio-long-term-ecg-monitoring-shows-consistent-performance-across-asian-and-non-asian-populations 2025-11-11T17:26:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/irhythm-s-zio-long-term-ecg-monitoring-shows-consistent-performance-across-asian-and-non-asian-populations 2025-11-11T17:26:09+00:00 hourly 0.9 https://trial.medpath.com/news/novel-monoclonal-antibody-f9h4-prevents-cd16a-b-shedding-to-enhance-nk-cell-mediated-cancer-immunotherapy 2025-11-11T17:24:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-monoclonal-antibody-f9h4-prevents-cd16a-b-shedding-to-enhance-nk-cell-mediated-cancer-immunotherapy 2025-11-11T17:24:30+00:00 hourly 0.9 https://trial.medpath.com/news/muna-therapeutics-initiates-phase-1-trial-of-novel-oral-trem2-agonist-mna-001-for-early-alzheimer-s-disease 2025-11-11T17:23:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/muna-therapeutics-initiates-phase-1-trial-of-novel-oral-trem2-agonist-mna-001-for-early-alzheimer-s-disease 2025-11-11T17:23:28+00:00 hourly 0.9 https://trial.medpath.com/news/pediatric-atopic-dermatitis-trials-shift-focus-to-patient-centered-outcomes 2025-11-11T17:23:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pediatric-atopic-dermatitis-trials-shift-focus-to-patient-centered-outcomes 2025-11-11T17:23:26+00:00 hourly 0.9 https://trial.medpath.com/news/merck-partners-with-kenyan-firm-to-establish-local-production-of-pediatric-schistosomiasis-treatment 2025-11-11T17:21:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-partners-with-kenyan-firm-to-establish-local-production-of-pediatric-schistosomiasis-treatment 2025-11-11T17:21:14+00:00 hourly 0.9 https://trial.medpath.com/news/engene-holdings-reports-63-complete-response-rate-in-phase-2-bladder-cancer-gene-therapy-trial 2025-11-11T17:21:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/engene-holdings-reports-63-complete-response-rate-in-phase-2-bladder-cancer-gene-therapy-trial 2025-11-11T17:21:02+00:00 hourly 0.9 https://trial.medpath.com/news/quoin-pharmaceuticals-achieves-high-concentration-topical-rapamycin-formulations-for-rare-vascular-malformations 2025-11-11T17:20:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quoin-pharmaceuticals-achieves-high-concentration-topical-rapamycin-formulations-for-rare-vascular-malformations 2025-11-11T17:20:34+00:00 hourly 0.9 https://trial.medpath.com/news/repair-biotechnologies-reports-atherosclerotic-plaque-regression-with-rep-0003-in-preclinical-study 2025-11-11T17:20:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/repair-biotechnologies-reports-atherosclerotic-plaque-regression-with-rep-0003-in-preclinical-study 2025-11-11T17:20:32+00:00 hourly 0.9 https://trial.medpath.com/news/mabwell-s-anti-il-11-antibody-9mw3811-becomes-world-s-first-il-11-therapeutic-to-enter-phase-ii-for-pathological-scarring 2025-11-11T17:19:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mabwell-s-anti-il-11-antibody-9mw3811-becomes-world-s-first-il-11-therapeutic-to-enter-phase-ii-for-pathological-scarring 2025-11-11T17:19:59+00:00 hourly 0.9 https://trial.medpath.com/news/allurion-advances-toward-fda-approval-with-zero-finding-inspections-and-5m-financing 2025-11-11T17:18:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allurion-advances-toward-fda-approval-with-zero-finding-inspections-and-5m-financing 2025-11-11T17:18:32+00:00 hourly 0.9 https://trial.medpath.com/news/satralizumab-demonstrates-17-4-reduction-in-pulmonary-vascular-resistance-in-biomarker-selected-pah-patients 2025-11-11T13:22:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/satralizumab-demonstrates-17-4-reduction-in-pulmonary-vascular-resistance-in-biomarker-selected-pah-patients 2025-11-11T13:22:40+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-car-t-therapy-outcomes-show-promise-despite-higher-toxicity-rates-in-diverse-patient-population 2025-11-11T13:21:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-car-t-therapy-outcomes-show-promise-despite-higher-toxicity-rates-in-diverse-patient-population 2025-11-11T13:21:46+00:00 hourly 0.9 https://trial.medpath.com/news/servier-india-launches-subsidized-biomarker-testing-initiative-for-aml-and-cholangiocarcinoma-patients 2025-11-11T13:20:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/servier-india-launches-subsidized-biomarker-testing-initiative-for-aml-and-cholangiocarcinoma-patients 2025-11-11T13:20:30+00:00 hourly 0.9 https://trial.medpath.com/news/zydus-lifesciences-secures-first-drug-approval-in-china-for-venlafaxine-er-capsules 2025-11-11T13:19:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zydus-lifesciences-secures-first-drug-approval-in-china-for-venlafaxine-er-capsules 2025-11-11T13:19:55+00:00 hourly 0.9 https://trial.medpath.com/news/mgi-tech-partners-with-south-africa-to-launch-110k-human-genome-program-and-deploy-africa-s-first-dnbseq-t7-sequencer 2025-11-11T13:18:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mgi-tech-partners-with-south-africa-to-launch-110k-human-genome-program-and-deploy-africa-s-first-dnbseq-t7-sequencer 2025-11-11T13:18:45+00:00 hourly 0.9 https://trial.medpath.com/news/mytomorrows-secures-29-million-to-expand-ai-powered-platform-for-pre-approval-treatment-access 2025-11-11T13:18:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mytomorrows-secures-29-million-to-expand-ai-powered-platform-for-pre-approval-treatment-access 2025-11-11T13:18:43+00:00 hourly 0.9 https://trial.medpath.com/news/granules-life-sciences-receives-first-us-fda-approval-for-hyderabad-manufacturing-facility 2025-11-11T13:18:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/granules-life-sciences-receives-first-us-fda-approval-for-hyderabad-manufacturing-facility 2025-11-11T13:18:20+00:00 hourly 0.9 https://trial.medpath.com/news/ai-adoption-accelerates-in-clinical-trials-as-industry-tackles-rising-complexity-and-white-space-inefficiencies 2025-11-11T12:24:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-adoption-accelerates-in-clinical-trials-as-industry-tackles-rising-complexity-and-white-space-inefficiencies 2025-11-11T12:24:25+00:00 hourly 0.9 https://trial.medpath.com/news/belenos-reports-promising-phase-1b-results-for-bel512-bispecific-in-atopic-dermatitis 2025-11-11T05:20:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/belenos-reports-promising-phase-1b-results-for-bel512-bispecific-in-atopic-dermatitis 2025-11-11T05:20:24+00:00 hourly 0.9 https://trial.medpath.com/news/shilpa-medicare-s-extended-release-ondansetron-injection-shows-superior-efficacy-in-phase-3-cinv-trial 2025-11-11T05:19:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shilpa-medicare-s-extended-release-ondansetron-injection-shows-superior-efficacy-in-phase-3-cinv-trial 2025-11-11T05:19:58+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-drug-m102-shows-promise-in-slowing-motor-neurone-disease-progression 2025-11-11T05:19:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experimental-drug-m102-shows-promise-in-slowing-motor-neurone-disease-progression 2025-11-11T05:19:19+00:00 hourly 0.9 https://trial.medpath.com/news/pcsk9-inhibitor-alirocumab-safely-reduces-cholesterol-by-50-in-heart-transplant-patients 2025-11-11T01:28:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pcsk9-inhibitor-alirocumab-safely-reduces-cholesterol-by-50-in-heart-transplant-patients 2025-11-11T01:28:07+00:00 hourly 0.9 https://trial.medpath.com/news/neurocrine-s-nbi-1070770-fails-to-meet-primary-endpoint-in-phase-ii-major-depressive-disorder-trial 2025-11-11T01:23:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurocrine-s-nbi-1070770-fails-to-meet-primary-endpoint-in-phase-ii-major-depressive-disorder-trial 2025-11-11T01:23:59+00:00 hourly 0.9 https://trial.medpath.com/news/quince-therapeutics-receives-positive-safety-review-for-ataxia-telangiectasia-treatment-in-phase-3-trial 2025-11-11T01:23:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quince-therapeutics-receives-positive-safety-review-for-ataxia-telangiectasia-treatment-in-phase-3-trial 2025-11-11T01:23:57+00:00 hourly 0.9 https://trial.medpath.com/news/sublingual-epinephrine-film-shows-comparable-safety-and-efficacy-in-pediatric-patients 2025-11-11T01:22:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sublingual-epinephrine-film-shows-comparable-safety-and-efficacy-in-pediatric-patients 2025-11-11T01:22:14+00:00 hourly 0.9 https://trial.medpath.com/news/capsovision-seeks-fda-breakthrough-device-designation-for-non-invasive-pancreatic-cancer-screening-capsule 2025-11-11T01:20:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/capsovision-seeks-fda-breakthrough-device-designation-for-non-invasive-pancreatic-cancer-screening-capsule 2025-11-11T01:20:18+00:00 hourly 0.9 https://trial.medpath.com/news/ivermectin-safety-trial-confirms-drug-can-be-safely-used-in-children-as-small-as-5-kg 2025-11-10T21:32:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ivermectin-safety-trial-confirms-drug-can-be-safely-used-in-children-as-small-as-5-kg 2025-11-10T21:32:24+00:00 hourly 0.9 https://trial.medpath.com/news/vittoria-biotherapeutics-to-present-first-in-human-car-t-data-for-t-cell-lymphoma-at-ash-2025 2025-11-10T21:30:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vittoria-biotherapeutics-to-present-first-in-human-car-t-data-for-t-cell-lymphoma-at-ash-2025 2025-11-10T21:30:13+00:00 hourly 0.9 https://trial.medpath.com/news/tizona-s-ttx-080-shows-dual-immune-activation-in-advanced-solid-tumors-advances-to-phase-1b-colorectal-cancer-trial 2025-11-10T21:28:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tizona-s-ttx-080-shows-dual-immune-activation-in-advanced-solid-tumors-advances-to-phase-1b-colorectal-cancer-trial 2025-11-10T21:28:50+00:00 hourly 0.9 https://trial.medpath.com/news/galecto-completes-285m-acquisition-of-damora-therapeutics-to-advance-rare-blood-cancer-pipeline 2025-11-10T21:28:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galecto-completes-285m-acquisition-of-damora-therapeutics-to-advance-rare-blood-cancer-pipeline 2025-11-10T21:28:25+00:00 hourly 0.9 https://trial.medpath.com/news/orbus-therapeutics-reports-positive-phase-3-stellar-trial-results-for-eflornithine-in-recurrent-idh-mutant-astrocytoma 2025-11-10T21:28:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orbus-therapeutics-reports-positive-phase-3-stellar-trial-results-for-eflornithine-in-recurrent-idh-mutant-astrocytoma 2025-11-10T21:28:16+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-expands-patent-litigation-against-denosumab-biosimilar-developers-in-latest-bpcia-filings 2025-11-10T21:27:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-expands-patent-litigation-against-denosumab-biosimilar-developers-in-latest-bpcia-filings 2025-11-10T21:27:29+00:00 hourly 0.9 https://trial.medpath.com/news/williams-cancer-institute-demonstrates-complete-tumor-resolution-with-combined-pulsed-electrical-field-ablation-and-intratumoral-immunotherapy 2025-11-10T21:26:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/williams-cancer-institute-demonstrates-complete-tumor-resolution-with-combined-pulsed-electrical-field-ablation-and-intratumoral-immunotherapy 2025-11-10T21:26:50+00:00 hourly 0.9 https://trial.medpath.com/news/imaging-biometrics-completes-phase-i-trial-of-gallium-maltolate-for-recurrent-glioblastoma 2025-11-10T21:25:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imaging-biometrics-completes-phase-i-trial-of-gallium-maltolate-for-recurrent-glioblastoma 2025-11-10T21:25:38+00:00 hourly 0.9 https://trial.medpath.com/news/zelenectide-pevedotin-demonstrates-promising-safety-and-efficacy-in-advanced-solid-tumors 2025-11-10T21:25:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zelenectide-pevedotin-demonstrates-promising-safety-and-efficacy-in-advanced-solid-tumors 2025-11-10T21:25:22+00:00 hourly 0.9 https://trial.medpath.com/news/athos-therapeutics-partners-with-xeptiva-to-deploy-ai-platform-for-veterinary-vaccine-biomarker-discovery 2025-11-10T21:24:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/athos-therapeutics-partners-with-xeptiva-to-deploy-ai-platform-for-veterinary-vaccine-biomarker-discovery 2025-11-10T21:24:45+00:00 hourly 0.9 https://trial.medpath.com/news/ascend-advanced-therapies-develops-proprietary-enhancers-boosting-aav-production-yields-up-to-3-fold 2025-11-10T21:24:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ascend-advanced-therapies-develops-proprietary-enhancers-boosting-aav-production-yields-up-to-3-fold 2025-11-10T21:24:20+00:00 hourly 0.9 https://trial.medpath.com/news/evidium-secures-22m-series-a-to-advance-transparent-healthcare-ai-platform 2025-11-10T21:24:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evidium-secures-22m-series-a-to-advance-transparent-healthcare-ai-platform 2025-11-10T21:24:09+00:00 hourly 0.9 https://trial.medpath.com/news/eco-animal-health-advances-toward-eu-approval-for-poultry-vaccine-targeting-mycoplasma-synoviae 2025-11-10T21:21:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eco-animal-health-advances-toward-eu-approval-for-poultry-vaccine-targeting-mycoplasma-synoviae 2025-11-10T21:21:55+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-avenzo-s-avzo-1418-for-egfr-mutated-nsclc 2025-11-10T21:20:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-avenzo-s-avzo-1418-for-egfr-mutated-nsclc 2025-11-10T21:20:52+00:00 hourly 0.9 https://trial.medpath.com/news/kenya-partners-with-africa-medicines-agency-to-accelerate-drug-registration-and-boost-local-manufacturing 2025-11-10T21:19:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kenya-partners-with-africa-medicines-agency-to-accelerate-drug-registration-and-boost-local-manufacturing 2025-11-10T21:19:52+00:00 hourly 0.9 https://trial.medpath.com/news/ps1-5m-connect-target-trial-launches-precision-medicine-approach-for-childhood-brain-cancer 2025-11-10T21:18:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ps1-5m-connect-target-trial-launches-precision-medicine-approach-for-childhood-brain-cancer 2025-11-10T21:18:53+00:00 hourly 0.9 https://trial.medpath.com/news/transition-bio-and-voyager-therapeutics-partner-to-develop-small-molecule-tdp-43-inhibitors-for-als-and-frontotemporal-dementia 2025-11-10T17:29:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transition-bio-and-voyager-therapeutics-partner-to-develop-small-molecule-tdp-43-inhibitors-for-als-and-frontotemporal-dementia 2025-11-10T17:29:01+00:00 hourly 0.9 https://trial.medpath.com/news/tuxedo-2-trial-shows-prasugrel-outperforms-ticagrelor-in-diabetic-patients-after-stent-placement 2025-11-10T17:26:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tuxedo-2-trial-shows-prasugrel-outperforms-ticagrelor-in-diabetic-patients-after-stent-placement 2025-11-10T17:26:22+00:00 hourly 0.9 https://trial.medpath.com/news/johns-hopkins-achieves-5-pancreatic-cancer-recurrence-rate-with-intraoperative-radiation-targeting-baltimore-triangle 2025-11-10T17:25:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johns-hopkins-achieves-5-pancreatic-cancer-recurrence-rate-with-intraoperative-radiation-targeting-baltimore-triangle 2025-11-10T17:25:32+00:00 hourly 0.9 https://trial.medpath.com/news/inflarx-s-oral-c5ar-inhibitor-inf904-shows-biologic-like-efficacy-in-phase-2a-trials-for-hidradenitis-suppurativa-and-chronic-spontaneous-urticaria 2025-11-10T17:24:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inflarx-s-oral-c5ar-inhibitor-inf904-shows-biologic-like-efficacy-in-phase-2a-trials-for-hidradenitis-suppurativa-and-chronic-spontaneous-urticaria 2025-11-10T17:24:54+00:00 hourly 0.9 https://trial.medpath.com/news/galectin-therapeutics-belapectin-shows-sustained-antifibrotic-effects-in-mash-cirrhosis-through-36-months 2025-11-10T17:24:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galectin-therapeutics-belapectin-shows-sustained-antifibrotic-effects-in-mash-cirrhosis-through-36-months 2025-11-10T17:24:52+00:00 hourly 0.9 https://trial.medpath.com/news/semaglutide-shows-cardiovascular-benefits-in-hiv-patients-with-fatty-liver-disease-in-slim-liver-trial 2025-11-10T17:24:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/semaglutide-shows-cardiovascular-benefits-in-hiv-patients-with-fatty-liver-disease-in-slim-liver-trial 2025-11-10T17:24:44+00:00 hourly 0.9 https://trial.medpath.com/news/voyager-therapeutics-advances-multi-modal-neurotherapeutics-pipeline-with-novel-neuroshuttle-platform-and-tdp-43-collaboration 2025-11-10T17:23:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/voyager-therapeutics-advances-multi-modal-neurotherapeutics-pipeline-with-novel-neuroshuttle-platform-and-tdp-43-collaboration 2025-11-10T17:23:30+00:00 hourly 0.9 https://trial.medpath.com/news/reviva-secures-european-patent-for-brilaroxazine-in-pulmonary-fibrosis-treatment 2025-11-10T17:22:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/reviva-secures-european-patent-for-brilaroxazine-in-pulmonary-fibrosis-treatment 2025-11-10T17:22:20+00:00 hourly 0.9 https://trial.medpath.com/news/liscure-biosciences-launches-phase-2-trial-of-first-in-class-lb-p8-for-primary-sclerosing-cholangitis 2025-11-10T17:22:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liscure-biosciences-launches-phase-2-trial-of-first-in-class-lb-p8-for-primary-sclerosing-cholangitis 2025-11-10T17:22:18+00:00 hourly 0.9 https://trial.medpath.com/news/geneseeq-s-pantrkaretm-receives-nmpa-approval-as-china-s-first-ngs-based-pan-solid-tumor-companion-diagnostic-for-ntrk-gene-fusions 2025-11-10T17:21:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/geneseeq-s-pantrkaretm-receives-nmpa-approval-as-china-s-first-ngs-based-pan-solid-tumor-companion-diagnostic-for-ntrk-gene-fusions 2025-11-10T17:21:33+00:00 hourly 0.9 https://trial.medpath.com/news/mannkind-discontinues-phase-3-trial-of-nebulized-clofazimine-for-ntm-lung-disease-due-to-futility 2025-11-10T17:21:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mannkind-discontinues-phase-3-trial-of-nebulized-clofazimine-for-ntm-lung-disease-due-to-futility 2025-11-10T17:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/tiumbio-s-dual-tgf-b-vegf-inhibitor-tosposertib-shows-70-6-response-rate-in-head-and-neck-cancer-trial 2025-11-10T17:20:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tiumbio-s-dual-tgf-b-vegf-inhibitor-tosposertib-shows-70-6-response-rate-in-head-and-neck-cancer-trial 2025-11-10T17:20:19+00:00 hourly 0.9 https://trial.medpath.com/news/armata-pharmaceuticals-commissions-state-of-the-art-cgmp-phage-manufacturing-facility-to-advance-antibiotic-resistant-infection-treatments 2025-11-10T17:20:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/armata-pharmaceuticals-commissions-state-of-the-art-cgmp-phage-manufacturing-facility-to-advance-antibiotic-resistant-infection-treatments 2025-11-10T17:20:03+00:00 hourly 0.9 https://trial.medpath.com/news/nurix-therapeutics-strengthens-board-with-former-pfizer-and-seagen-executive-roger-dansey 2025-11-10T17:19:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nurix-therapeutics-strengthens-board-with-former-pfizer-and-seagen-executive-roger-dansey 2025-11-10T17:19:43+00:00 hourly 0.9 https://trial.medpath.com/news/vascarta-s-sto-1-achieves-67-survival-rate-in-preclinical-glioblastoma-study 2025-11-10T17:19:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vascarta-s-sto-1-achieves-67-survival-rate-in-preclinical-glioblastoma-study 2025-11-10T17:19:36+00:00 hourly 0.9 https://trial.medpath.com/news/tandem-diabetes-secures-fda-approval-for-mobi-android-app-stock-surges-20 2025-11-10T17:19:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tandem-diabetes-secures-fda-approval-for-mobi-android-app-stock-surges-20 2025-11-10T17:19:31+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-opens-new-radioligand-therapy-manufacturing-facility-in-california-as-part-of-23-billion-us-expansion 2025-11-10T17:19:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-opens-new-radioligand-therapy-manufacturing-facility-in-california-as-part-of-23-billion-us-expansion 2025-11-10T17:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/venus-concept-receives-fda-510-k-clearance-for-venus-nova-multi-application-aesthetic-platform 2025-11-10T17:18:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/venus-concept-receives-fda-510-k-clearance-for-venus-nova-multi-application-aesthetic-platform 2025-11-10T17:18:04+00:00 hourly 0.9 https://trial.medpath.com/news/akeso-s-ak135-shows-promise-for-chemotherapy-induced-neuropathy-in-preclinical-studies 2025-11-10T17:17:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akeso-s-ak135-shows-promise-for-chemotherapy-induced-neuropathy-in-preclinical-studies 2025-11-10T17:17:34+00:00 hourly 0.9 https://trial.medpath.com/news/poly-hf-trial-polypill-strategy-improves-heart-function-and-reduces-hospitalizations-in-heart-failure-patients 2025-11-10T17:16:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/poly-hf-trial-polypill-strategy-improves-heart-function-and-reduces-hospitalizations-in-heart-failure-patients 2025-11-10T17:16:36+00:00 hourly 0.9 https://trial.medpath.com/news/sino-biopharm-and-meditrust-health-partner-to-advance-drug-insurance-integration-model-in-china 2025-11-10T13:23:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sino-biopharm-and-meditrust-health-partner-to-advance-drug-insurance-integration-model-in-china 2025-11-10T13:23:10+00:00 hourly 0.9 https://trial.medpath.com/news/leucid-bio-s-novel-car-t-therapy-leu011-shows-proof-of-concept-in-solid-tumors-with-encouraging-safety-profile 2025-11-10T13:22:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leucid-bio-s-novel-car-t-therapy-leu011-shows-proof-of-concept-in-solid-tumors-with-encouraging-safety-profile 2025-11-10T13:22:27+00:00 hourly 0.9 https://trial.medpath.com/news/uk-high-court-clears-path-for-alvotech-s-eylea-biosimilar-manufacturing-ahead-of-patent-expiry 2025-11-10T13:21:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-high-court-clears-path-for-alvotech-s-eylea-biosimilar-manufacturing-ahead-of-patent-expiry 2025-11-10T13:21:19+00:00 hourly 0.9 https://trial.medpath.com/news/rona-therapeutics-rn0361-sirna-demonstrates-93-apoc3-reduction-in-phase-1-trial-for-severe-hypertriglyceridemia 2025-11-10T13:21:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rona-therapeutics-rn0361-sirna-demonstrates-93-apoc3-reduction-in-phase-1-trial-for-severe-hypertriglyceridemia 2025-11-10T13:21:08+00:00 hourly 0.9 https://trial.medpath.com/news/glenmark-receives-china-approval-for-ryaltris-nasal-spray-first-fixed-dose-combination-for-allergic-rhinitis 2025-11-10T13:21:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glenmark-receives-china-approval-for-ryaltris-nasal-spray-first-fixed-dose-combination-for-allergic-rhinitis 2025-11-10T13:21:06+00:00 hourly 0.9 https://trial.medpath.com/news/simcere-s-il-2-mutant-fusion-protein-sim0278-advances-to-phase-ii-trial-for-atopic-dermatitis 2025-11-10T13:20:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/simcere-s-il-2-mutant-fusion-protein-sim0278-advances-to-phase-ii-trial-for-atopic-dermatitis 2025-11-10T13:20:33+00:00 hourly 0.9 https://trial.medpath.com/news/exact-sciences-blood-test-shows-seven-fold-improvement-in-early-liver-cancer-detection-over-standard-ultrasound 2025-11-10T13:20:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exact-sciences-blood-test-shows-seven-fold-improvement-in-early-liver-cancer-detection-over-standard-ultrasound 2025-11-10T13:20:12+00:00 hourly 0.9 https://trial.medpath.com/news/revvity-partners-with-eli-lilly-to-democratize-ai-drug-discovery-through-tunelab-platform-integration 2025-11-10T13:11:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revvity-partners-with-eli-lilly-to-democratize-ai-drug-discovery-through-tunelab-platform-integration 2025-11-10T13:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/innate-pharma-receives-fda-clearance-for-phase-3-trial-of-lacutamab-in-cutaneous-t-cell-lymphoma 2025-11-10T09:28:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innate-pharma-receives-fda-clearance-for-phase-3-trial-of-lacutamab-in-cutaneous-t-cell-lymphoma 2025-11-10T09:28:50+00:00 hourly 0.9 https://trial.medpath.com/news/avingtrans-subsidiary-adaptix-receives-fda-510-k-clearance-for-revolutionary-3d-orthopaedic-imaging-system 2025-11-10T09:28:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avingtrans-subsidiary-adaptix-receives-fda-510-k-clearance-for-revolutionary-3d-orthopaedic-imaging-system 2025-11-10T09:28:47+00:00 hourly 0.9 https://trial.medpath.com/news/chong-kun-dang-showcases-three-promising-drug-candidates-at-major-u-s-medical-conferences 2025-11-10T05:22:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chong-kun-dang-showcases-three-promising-drug-candidates-at-major-u-s-medical-conferences 2025-11-10T05:22:42+00:00 hourly 0.9 https://trial.medpath.com/news/innovent-and-sanegenebio-report-promising-phase-1-results-for-ibi3016-sirna-hypertension-therapy 2025-11-10T05:19:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovent-and-sanegenebio-report-promising-phase-1-results-for-ibi3016-sirna-hypertension-therapy 2025-11-10T05:19:52+00:00 hourly 0.9 https://trial.medpath.com/news/targeted-vitamin-d3-supplementation-cuts-heart-attack-recurrence-risk-by-50-in-clinical-trial 2025-11-10T01:21:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/targeted-vitamin-d3-supplementation-cuts-heart-attack-recurrence-risk-by-50-in-clinical-trial 2025-11-10T01:21:23+00:00 hourly 0.9 https://trial.medpath.com/news/humacyte-s-bioengineered-vessel-shows-superior-performance-in-high-risk-dialysis-patients-over-two-years 2025-11-10T01:19:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/humacyte-s-bioengineered-vessel-shows-superior-performance-in-high-risk-dialysis-patients-over-two-years 2025-11-10T01:19:31+00:00 hourly 0.9 https://trial.medpath.com/news/visionary-holdings-launches-medical-grade-stem-cell-anti-aging-product-line-in-asia 2025-11-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/visionary-holdings-launches-medical-grade-stem-cell-anti-aging-product-line-in-asia 2025-11-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/calidi-biotherapeutics-advances-cld-401-oncolytic-virus-therapy-toward-ind-filing-in-q4-2026 2025-11-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/calidi-biotherapeutics-advances-cld-401-oncolytic-virus-therapy-toward-ind-filing-in-q4-2026 2025-11-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-receptor-agonists-show-no-increased-pancreatitis-risk-in-high-triglyceride-patients-study-finds 2025-11-09T21:21:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-receptor-agonists-show-no-increased-pancreatitis-risk-in-high-triglyceride-patients-study-finds 2025-11-09T21:21:22+00:00 hourly 0.9 https://trial.medpath.com/news/george-medicines-reports-sustained-blood-pressure-control-with-widaplik-triple-combination-therapy-in-52-week-extension-study 2025-11-09T17:19:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/george-medicines-reports-sustained-blood-pressure-control-with-widaplik-triple-combination-therapy-in-52-week-extension-study 2025-11-09T17:19:47+00:00 hourly 0.9 https://trial.medpath.com/news/metformin-shows-promise-in-reducing-atrial-fibrillation-recurrence-after-catheter-ablation 2025-11-09T17:19:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metformin-shows-promise-in-reducing-atrial-fibrillation-recurrence-after-catheter-ablation 2025-11-09T17:19:31+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-engineer-human-stomach-cells-to-produce-insulin-for-type-1-diabetes-treatment 2025-11-09T17:19:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-engineer-human-stomach-cells-to-produce-insulin-for-type-1-diabetes-treatment 2025-11-09T17:19:18+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-discover-novel-antibiotic-class-with-potent-activity-against-drug-resistant-bacteria 2025-11-09T17:19:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-discover-novel-antibiotic-class-with-potent-activity-against-drug-resistant-bacteria 2025-11-09T17:19:07+00:00 hourly 0.9 https://trial.medpath.com/news/metformin-may-blunt-exercise-benefits-in-diabetes-prevention-rutgers-study-finds 2025-11-09T17:18:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metformin-may-blunt-exercise-benefits-in-diabetes-prevention-rutgers-study-finds 2025-11-09T17:18:53+00:00 hourly 0.9 https://trial.medpath.com/news/novel-nomogram-predicts-survival-outcomes-for-advanced-nsclc-patients-receiving-immunotherapy-beyond-progression 2025-11-09T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-nomogram-predicts-survival-outcomes-for-advanced-nsclc-patients-receiving-immunotherapy-beyond-progression 2025-11-09T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/zinzino-acquires-mexican-health-company-sanki-for-8-million-to-expand-americas-distribution-network 2025-11-09T13:19:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zinzino-acquires-mexican-health-company-sanki-for-8-million-to-expand-americas-distribution-network 2025-11-09T13:19:46+00:00 hourly 0.9 https://trial.medpath.com/news/sibeprenlimab-demonstrates-54-proteinuria-reduction-in-largest-phase-3-iga-nephropathy-trial 2025-11-09T09:19:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sibeprenlimab-demonstrates-54-proteinuria-reduction-in-largest-phase-3-iga-nephropathy-trial 2025-11-09T09:19:59+00:00 hourly 0.9 https://trial.medpath.com/news/fda-investigates-byheart-baby-formula-after-13-infants-hospitalized-with-botulism-across-10-states 2025-11-09T01:22:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-investigates-byheart-baby-formula-after-13-infants-hospitalized-with-botulism-across-10-states 2025-11-09T01:22:37+00:00 hourly 0.9 https://trial.medpath.com/news/vtama-cream-shows-49-5-response-rate-in-pediatric-atopic-dermatitis-patients-without-comorbidities 2025-11-09T01:21:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vtama-cream-shows-49-5-response-rate-in-pediatric-atopic-dermatitis-patients-without-comorbidities 2025-11-09T01:21:31+00:00 hourly 0.9 https://trial.medpath.com/news/shortened-dual-anticoagulation-therapy-after-stent-placement-shows-equal-efficacy-with-reduced-bleeding-risk-in-afib-patients 2025-11-09T01:20:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shortened-dual-anticoagulation-therapy-after-stent-placement-shows-equal-efficacy-with-reduced-bleeding-risk-in-afib-patients 2025-11-09T01:20:13+00:00 hourly 0.9 https://trial.medpath.com/news/optigo-biotherapeutics-appoints-industry-veteran-andreas-wallnofer-to-board-as-long-acting-anti-vegf-advances-to-ind-enabling-studies 2025-11-08T21:28:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/optigo-biotherapeutics-appoints-industry-veteran-andreas-wallnofer-to-board-as-long-acting-anti-vegf-advances-to-ind-enabling-studies 2025-11-08T21:28:38+00:00 hourly 0.9 https://trial.medpath.com/news/fish-oil-supplementation-reduces-cardiovascular-events-by-43-in-dialysis-patients-pisces-trial-shows 2025-11-08T21:28:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fish-oil-supplementation-reduces-cardiovascular-events-by-43-in-dialysis-patients-pisces-trial-shows 2025-11-08T21:28:14+00:00 hourly 0.9 https://trial.medpath.com/news/pelthos-therapeutics-acquires-xepi-for-antibiotic-resistant-impetigo-treatment-and-secures-18-million-financing 2025-11-08T21:27:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pelthos-therapeutics-acquires-xepi-for-antibiotic-resistant-impetigo-treatment-and-secures-18-million-financing 2025-11-08T21:27:01+00:00 hourly 0.9 https://trial.medpath.com/news/chlorotoxin-based-car-t-cell-therapy-demonstrates-safety-and-feasibility-in-recurrent-glioblastoma-phase-1-trial 2025-11-08T21:22:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chlorotoxin-based-car-t-cell-therapy-demonstrates-safety-and-feasibility-in-recurrent-glioblastoma-phase-1-trial 2025-11-08T21:22:26+00:00 hourly 0.9 https://trial.medpath.com/news/hot-flashes-treatment-pipeline-expands-with-15-novel-therapies-from-leading-pharmaceutical-companies 2025-11-08T21:22:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hot-flashes-treatment-pipeline-expands-with-15-novel-therapies-from-leading-pharmaceutical-companies 2025-11-08T21:22:15+00:00 hourly 0.9 https://trial.medpath.com/news/sotagliflozin-shows-significant-benefits-in-heart-failure-patients-with-preserved-ejection-fraction-without-diabetes 2025-11-08T21:20:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sotagliflozin-shows-significant-benefits-in-heart-failure-patients-with-preserved-ejection-fraction-without-diabetes 2025-11-08T21:20:04+00:00 hourly 0.9 https://trial.medpath.com/news/ohsu-researchers-develop-novel-cancer-drug-su212-targeting-triple-negative-breast-cancer 2025-11-08T21:20:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ohsu-researchers-develop-novel-cancer-drug-su212-targeting-triple-negative-breast-cancer 2025-11-08T21:20:01+00:00 hourly 0.9 https://trial.medpath.com/news/triple-receptor-agonist-dr10624-shows-promise-in-phase-ii-trial-for-severe-hypertriglyceridemia 2025-11-08T21:19:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/triple-receptor-agonist-dr10624-shows-promise-in-phase-ii-trial-for-severe-hypertriglyceridemia 2025-11-08T21:19:04+00:00 hourly 0.9 https://trial.medpath.com/news/sanegenebio-partners-with-eli-lilly-in-1-2-billion-rnai-collaboration-for-metabolic-diseases 2025-11-08T21:19:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanegenebio-partners-with-eli-lilly-in-1-2-billion-rnai-collaboration-for-metabolic-diseases 2025-11-08T21:19:02+00:00 hourly 0.9 https://trial.medpath.com/news/sparsentan-shows-superior-proteinuria-reduction-in-pediatric-fsgs-patients-compared-to-standard-care 2025-11-08T21:18:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sparsentan-shows-superior-proteinuria-reduction-in-pediatric-fsgs-patients-compared-to-standard-care 2025-11-08T21:18:57+00:00 hourly 0.9 https://trial.medpath.com/news/immunic-s-vidofludimus-calcium-shows-promising-ms-data-as-phase-3-trials-approach-2026-readout 2025-11-08T17:21:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunic-s-vidofludimus-calcium-shows-promising-ms-data-as-phase-3-trials-approach-2026-readout 2025-11-08T17:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/inflarx-stock-surges-67-5-ahead-of-critical-phase-2a-trial-results-for-inf904 2025-11-08T17:20:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inflarx-stock-surges-67-5-ahead-of-critical-phase-2a-trial-results-for-inf904 2025-11-08T17:20:49+00:00 hourly 0.9 https://trial.medpath.com/news/inka-health-publishes-framework-to-enable-cross-border-use-of-real-world-evidence-in-oncology 2025-11-08T17:20:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inka-health-publishes-framework-to-enable-cross-border-use-of-real-world-evidence-in-oncology 2025-11-08T17:20:40+00:00 hourly 0.9 https://trial.medpath.com/news/ccp-approves-getz-group-s-acquisition-of-novartis-pakistan-in-major-pharmaceutical-transaction 2025-11-08T17:19:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ccp-approves-getz-group-s-acquisition-of-novartis-pakistan-in-major-pharmaceutical-transaction 2025-11-08T17:19:14+00:00 hourly 0.9 https://trial.medpath.com/news/phase-ii-trial-shows-promise-for-toripalimab-flot-combination-in-gastric-cancer-with-peritoneal-metastasis 2025-11-08T17:18:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-ii-trial-shows-promise-for-toripalimab-flot-combination-in-gastric-cancer-with-peritoneal-metastasis 2025-11-08T17:18:24+00:00 hourly 0.9 https://trial.medpath.com/news/onconaut-therapeutics-secures-2-5m-nih-grant-to-advance-chd1l-inhibitors-for-metastatic-colorectal-cancer 2025-11-08T13:18:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onconaut-therapeutics-secures-2-5m-nih-grant-to-advance-chd1l-inhibitors-for-metastatic-colorectal-cancer 2025-11-08T13:18:56+00:00 hourly 0.9 https://trial.medpath.com/news/hikma-launches-first-us-biosimilar-starjemza-seventh-ustekinumab-alternative-to-enter-market 2025-11-08T09:20:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hikma-launches-first-us-biosimilar-starjemza-seventh-ustekinumab-alternative-to-enter-market 2025-11-08T09:20:44+00:00 hourly 0.9 https://trial.medpath.com/news/kardigan-s-ataciguat-shows-promise-in-phase-2-trial-for-moderate-calcific-aortic-valve-stenosis 2025-11-08T05:20:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kardigan-s-ataciguat-shows-promise-in-phase-2-trial-for-moderate-calcific-aortic-valve-stenosis 2025-11-08T05:20:18+00:00 hourly 0.9 https://trial.medpath.com/news/ng101-shows-promise-in-phase-2-trial-for-glp-1-induced-nausea-and-vomiting 2025-11-08T01:27:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ng101-shows-promise-in-phase-2-trial-for-glp-1-induced-nausea-and-vomiting 2025-11-08T01:27:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-places-clinical-hold-on-tenaya-s-gene-therapy-trial-for-rare-heart-disease 2025-11-08T01:26:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-places-clinical-hold-on-tenaya-s-gene-therapy-trial-for-rare-heart-disease 2025-11-08T01:26:38+00:00 hourly 0.9 https://trial.medpath.com/news/taiho-pharmaceutical-challenges-uspto-over-1-billion-lytgobi-patent-extension-denial 2025-11-08T01:22:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taiho-pharmaceutical-challenges-uspto-over-1-billion-lytgobi-patent-extension-denial 2025-11-08T01:22:33+00:00 hourly 0.9 https://trial.medpath.com/news/inflarx-to-report-phase-2a-results-for-oral-c5ar-inhibitor-inf904-in-hidradenitis-suppurativa-and-chronic-spontaneous-urticaria 2025-11-08T01:21:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inflarx-to-report-phase-2a-results-for-oral-c5ar-inhibitor-inf904-in-hidradenitis-suppurativa-and-chronic-spontaneous-urticaria 2025-11-08T01:21:03+00:00 hourly 0.9 https://trial.medpath.com/news/novel-nano-formulated-cbd-delivers-rapid-neuropathic-pain-relief-in-preclinical-study 2025-11-08T01:19:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-nano-formulated-cbd-delivers-rapid-neuropathic-pain-relief-in-preclinical-study 2025-11-08T01:19:34+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-identifies-patient-subtypes-most-likely-to-benefit-from-cobenfy-first-new-schizophrenia-drug-in-50-years 2025-11-08T01:18:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-identifies-patient-subtypes-most-likely-to-benefit-from-cobenfy-first-new-schizophrenia-drug-in-50-years 2025-11-08T01:18:53+00:00 hourly 0.9 https://trial.medpath.com/news/synchron-secures-200m-series-d-to-commercialize-brain-computer-interface-platform 2025-11-08T01:18:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/synchron-secures-200m-series-d-to-commercialize-brain-computer-interface-platform 2025-11-08T01:18:43+00:00 hourly 0.9 https://trial.medpath.com/news/assembly-biosciences-reports-positive-phase-1b-results-for-next-generation-hepatitis-b-capsid-assembly-modulator-abi-4334 2025-11-07T21:27:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/assembly-biosciences-reports-positive-phase-1b-results-for-next-generation-hepatitis-b-capsid-assembly-modulator-abi-4334 2025-11-07T21:27:02+00:00 hourly 0.9 https://trial.medpath.com/news/urogen-pharma-gains-fda-pathway-for-ugn-103-as-zusduri-achieves-record-early-demand 2025-11-07T21:24:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/urogen-pharma-gains-fda-pathway-for-ugn-103-as-zusduri-achieves-record-early-demand 2025-11-07T21:24:16+00:00 hourly 0.9 https://trial.medpath.com/news/immunocore-s-imc-i109v-shows-promising-antiviral-activity-in-phase-1-hepatitis-b-trial 2025-11-07T21:24:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunocore-s-imc-i109v-shows-promising-antiviral-activity-in-phase-1-hepatitis-b-trial 2025-11-07T21:24:07+00:00 hourly 0.9 https://trial.medpath.com/news/rutgers-cancer-institute-reports-breakthrough-t-cell-therapies-achieve-long-term-remission-in-hpv-associated-cancers 2025-11-07T21:23:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rutgers-cancer-institute-reports-breakthrough-t-cell-therapies-achieve-long-term-remission-in-hpv-associated-cancers 2025-11-07T21:23:09+00:00 hourly 0.9 https://trial.medpath.com/news/proton-pump-inhibitors-linked-to-worse-breast-cancer-outcomes-in-large-international-study 2025-11-07T21:22:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proton-pump-inhibitors-linked-to-worse-breast-cancer-outcomes-in-large-international-study 2025-11-07T21:22:20+00:00 hourly 0.9 https://trial.medpath.com/news/optigo-biotherapeutics-advances-long-acting-anti-vegf-therapy-xpk-640-toward-ind-enabling-studies 2025-11-07T21:22:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/optigo-biotherapeutics-advances-long-acting-anti-vegf-therapy-xpk-640-toward-ind-enabling-studies 2025-11-07T21:22:03+00:00 hourly 0.9 https://trial.medpath.com/news/tissue-regenix-faces-urgent-funding-crisis-as-regenerative-medicine-company-seeks-ps5m-to-avoid-insolvency 2025-11-07T21:22:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tissue-regenix-faces-urgent-funding-crisis-as-regenerative-medicine-company-seeks-ps5m-to-avoid-insolvency 2025-11-07T21:22:01+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-s-mezagitamab-shows-sustained-kidney-protection-18-months-after-treatment-in-iga-nephropathy 2025-11-07T21:20:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/takeda-s-mezagitamab-shows-sustained-kidney-protection-18-months-after-treatment-in-iga-nephropathy 2025-11-07T21:20:48+00:00 hourly 0.9 https://trial.medpath.com/news/cranial-technologies-brings-fda-cleared-doc-band-r-infant-head-reshaping-treatment-to-china-following-nmpa-approval 2025-11-07T21:20:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cranial-technologies-brings-fda-cleared-doc-band-r-infant-head-reshaping-treatment-to-china-following-nmpa-approval 2025-11-07T21:20:31+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-s-trodelvy-fails-primary-endpoint-in-first-line-hr-her2-metastatic-breast-cancer-trial 2025-11-07T17:27:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gilead-s-trodelvy-fails-primary-endpoint-in-first-line-hr-her2-metastatic-breast-cancer-trial 2025-11-07T17:27:16+00:00 hourly 0.9 https://trial.medpath.com/news/indapta-s-allogeneic-nk-cell-therapy-shows-promising-activity-in-heavily-pretreated-multiple-myeloma-patients 2025-11-07T17:25:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indapta-s-allogeneic-nk-cell-therapy-shows-promising-activity-in-heavily-pretreated-multiple-myeloma-patients 2025-11-07T17:25:53+00:00 hourly 0.9 https://trial.medpath.com/news/sequential-pd-1-inhibitors-show-promise-as-consolidation-therapy-following-cd19-car-t-treatment-in-relapsed-nhl 2025-11-07T17:23:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sequential-pd-1-inhibitors-show-promise-as-consolidation-therapy-following-cd19-car-t-treatment-in-relapsed-nhl 2025-11-07T17:23:34+00:00 hourly 0.9 https://trial.medpath.com/news/genvivo-reports-positive-phase-1-results-for-gen2-off-the-shelf-cancer-immunotherapy 2025-11-07T17:23:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genvivo-reports-positive-phase-1-results-for-gen2-off-the-shelf-cancer-immunotherapy 2025-11-07T17:23:28+00:00 hourly 0.9 https://trial.medpath.com/news/metavia-s-vanoglipel-shows-dual-benefits-in-mash-phase-2a-trial-with-significant-hba1c-reduction-and-liver-improvements 2025-11-07T17:22:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metavia-s-vanoglipel-shows-dual-benefits-in-mash-phase-2a-trial-with-significant-hba1c-reduction-and-liver-improvements 2025-11-07T17:22:30+00:00 hourly 0.9 https://trial.medpath.com/news/stk-012-combination-shows-57-response-rate-in-pd-l1-negative-nsclc-phase-1-trial 2025-11-07T17:21:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stk-012-combination-shows-57-response-rate-in-pd-l1-negative-nsclc-phase-1-trial 2025-11-07T17:21:51+00:00 hourly 0.9 https://trial.medpath.com/news/io-biotech-unveils-promising-preclinical-data-for-next-generation-cancer-vaccines-targeting-tumor-microenvironment 2025-11-07T17:21:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/io-biotech-unveils-promising-preclinical-data-for-next-generation-cancer-vaccines-targeting-tumor-microenvironment 2025-11-07T17:21:25+00:00 hourly 0.9 https://trial.medpath.com/news/eledon-advances-kidney-transplant-drug-to-phase-iii-despite-missing-primary-endpoint-in-phase-ii-trial 2025-11-07T17:20:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eledon-advances-kidney-transplant-drug-to-phase-iii-despite-missing-primary-endpoint-in-phase-ii-trial 2025-11-07T17:20:44+00:00 hourly 0.9 https://trial.medpath.com/news/oncoinvent-launches-nok-130-million-rights-issue-to-advance-radspherin-radiopharmaceutical-therapy 2025-11-07T17:20:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncoinvent-launches-nok-130-million-rights-issue-to-advance-radspherin-radiopharmaceutical-therapy 2025-11-07T17:20:21+00:00 hourly 0.9 https://trial.medpath.com/news/abzena-and-mabqi-form-strategic-partnership-to-streamline-antibody-drug-development 2025-11-07T17:20:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abzena-and-mabqi-form-strategic-partnership-to-streamline-antibody-drug-development 2025-11-07T17:20:09+00:00 hourly 0.9 https://trial.medpath.com/news/brii-biosciences-combination-therapy-shows-promise-for-hepatitis-b-functional-cure-in-phase-2-study 2025-11-07T17:20:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brii-biosciences-combination-therapy-shows-promise-for-hepatitis-b-functional-cure-in-phase-2-study 2025-11-07T17:20:01+00:00 hourly 0.9 https://trial.medpath.com/news/iqirvo-shows-sustained-long-term-benefits-in-primary-biliary-cholangitis-with-novel-fatigue-mechanism-insights 2025-11-07T17:19:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iqirvo-shows-sustained-long-term-benefits-in-primary-biliary-cholangitis-with-novel-fatigue-mechanism-insights 2025-11-07T17:19:23+00:00 hourly 0.9 https://trial.medpath.com/news/shield-therapeutics-accrufer-receives-marketing-approval-in-south-korea-for-iron-deficiency-treatment 2025-11-07T13:21:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shield-therapeutics-accrufer-receives-marketing-approval-in-south-korea-for-iron-deficiency-treatment 2025-11-07T13:21:53+00:00 hourly 0.9 https://trial.medpath.com/news/biomunex-unveils-mait-engager-platform-data-at-sitc-2025-targeting-enhanced-cancer-immunotherapy-safety 2025-11-07T13:19:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomunex-unveils-mait-engager-platform-data-at-sitc-2025-targeting-enhanced-cancer-immunotherapy-safety 2025-11-07T13:19:49+00:00 hourly 0.9 https://trial.medpath.com/news/lupus-nephritis-drug-market-transforms-with-targeted-therapies-as-unmet-medical-needs-drive-innovation 2025-11-07T13:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupus-nephritis-drug-market-transforms-with-targeted-therapies-as-unmet-medical-needs-drive-innovation 2025-11-07T13:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/onchilles-pharma-receives-fda-clearance-for-first-in-class-elane-pathway-cancer-therapeutic-n17350 2025-11-07T11:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onchilles-pharma-receives-fda-clearance-for-first-in-class-elane-pathway-cancer-therapeutic-n17350 2025-11-07T11:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/oncotelic-therapeutics-joint-venture-identifies-biomarker-signature-for-precision-mtor-inhibitor-therapy 2025-11-07T11:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncotelic-therapeutics-joint-venture-identifies-biomarker-signature-for-precision-mtor-inhibitor-therapy 2025-11-07T11:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/aquestive-therapeutics-advances-global-regulatory-strategy-for-anaphylm-epinephrine-sublingual-film 2025-11-07T10:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aquestive-therapeutics-advances-global-regulatory-strategy-for-anaphylm-epinephrine-sublingual-film 2025-11-07T10:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/esmo-2025-highlights-transformative-advances-in-cancer-treatment-adcs-move-to-earlier-disease-settings-while-ai-integration-accelerates 2025-11-07T09:58:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/esmo-2025-highlights-transformative-advances-in-cancer-treatment-adcs-move-to-earlier-disease-settings-while-ai-integration-accelerates 2025-11-07T09:58:37+00:00 hourly 0.9 https://trial.medpath.com/news/independent-vaccine-experts-launch-review-of-hepatitis-b-birth-vaccination-data-following-cdc-panel-delay 2025-11-07T09:23:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/independent-vaccine-experts-launch-review-of-hepatitis-b-birth-vaccination-data-following-cdc-panel-delay 2025-11-07T09:23:32+00:00 hourly 0.9 https://trial.medpath.com/news/mbx-biosciences-raises-150-million-to-advance-canvuparatide-into-phase-iii-trials 2025-11-07T09:19:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mbx-biosciences-raises-150-million-to-advance-canvuparatide-into-phase-iii-trials 2025-11-07T09:19:57+00:00 hourly 0.9 https://trial.medpath.com/news/japanese-consortium-develops-ai-powered-cancer-vaccines-targeting-dark-genome-antigens 2025-11-07T09:19:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japanese-consortium-develops-ai-powered-cancer-vaccines-targeting-dark-genome-antigens 2025-11-07T09:19:52+00:00 hourly 0.9 https://trial.medpath.com/news/oric-pharmaceuticals-publishes-breakthrough-research-on-brain-penetrant-egfr-inhibitor-enozertinib-for-lung-cancer 2025-11-07T05:23:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oric-pharmaceuticals-publishes-breakthrough-research-on-brain-penetrant-egfr-inhibitor-enozertinib-for-lung-cancer 2025-11-07T05:23:26+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-announces-major-price-cuts-for-glp-1-weight-loss-drugs-through-trumprx-initiative 2025-11-07T05:22:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-announces-major-price-cuts-for-glp-1-weight-loss-drugs-through-trumprx-initiative 2025-11-07T05:22:50+00:00 hourly 0.9 https://trial.medpath.com/news/canadian-researchers-develop-next-generation-car-t-therapy-targeting-solid-tumors-with-mesothelin 2025-11-07T05:21:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/canadian-researchers-develop-next-generation-car-t-therapy-targeting-solid-tumors-with-mesothelin 2025-11-07T05:21:27+00:00 hourly 0.9 https://trial.medpath.com/news/nj-bio-expands-translational-research-capabilities-through-l2p-research-labs-asset-acquisition 2025-11-07T05:21:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nj-bio-expands-translational-research-capabilities-through-l2p-research-labs-asset-acquisition 2025-11-07T05:21:19+00:00 hourly 0.9 https://trial.medpath.com/news/best-vascular-novoste-celebrates-25-years-of-fda-approved-vascular-brachytherapy-for-coronary-restenosis 2025-11-07T05:20:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/best-vascular-novoste-celebrates-25-years-of-fda-approved-vascular-brachytherapy-for-coronary-restenosis 2025-11-07T05:20:37+00:00 hourly 0.9 https://trial.medpath.com/news/cardiff-oncology-reports-positive-phase-2-data-for-plk1-inhibitor-onvansertib-in-ras-mutated-colorectal-cancer 2025-11-07T01:25:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cardiff-oncology-reports-positive-phase-2-data-for-plk1-inhibitor-onvansertib-in-ras-mutated-colorectal-cancer 2025-11-07T01:25:34+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-accelerates-pf-08634404-bispecific-development-with-multiple-phase-3-trials-following-1-25b-3sbio-deal 2025-11-07T01:22:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-accelerates-pf-08634404-bispecific-development-with-multiple-phase-3-trials-following-1-25b-3sbio-deal 2025-11-07T01:22:58+00:00 hourly 0.9 https://trial.medpath.com/news/supremo-trial-shows-chest-wall-radiation-may-be-omitted-in-intermediate-risk-breast-cancer-without-compromising-survival 2025-11-07T01:22:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/supremo-trial-shows-chest-wall-radiation-may-be-omitted-in-intermediate-risk-breast-cancer-without-compromising-survival 2025-11-07T01:22:26+00:00 hourly 0.9 https://trial.medpath.com/news/pliant-therapeutics-reports-promising-50-response-rate-for-pln-101095-in-checkpoint-resistant-solid-tumors 2025-11-07T01:21:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pliant-therapeutics-reports-promising-50-response-rate-for-pln-101095-in-checkpoint-resistant-solid-tumors 2025-11-07T01:21:55+00:00 hourly 0.9 https://trial.medpath.com/news/sutro-biopharma-receives-fda-clearance-for-stro-004-tissue-factor-adc-advances-dual-payload-platform 2025-11-07T01:21:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sutro-biopharma-receives-fda-clearance-for-stro-004-tissue-factor-adc-advances-dual-payload-platform 2025-11-07T01:21:49+00:00 hourly 0.9 https://trial.medpath.com/news/cms-launches-generous-model-to-implement-most-favored-nation-pricing-for-medicaid-prescription-drugs 2025-11-07T01:21:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cms-launches-generous-model-to-implement-most-favored-nation-pricing-for-medicaid-prescription-drugs 2025-11-07T01:21:41+00:00 hourly 0.9 https://trial.medpath.com/news/forbion-closes-eur200-million-bioeconomy-fund-to-drive-sustainable-biotechnology-innovation 2025-11-07T01:21:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/forbion-closes-eur200-million-bioeconomy-fund-to-drive-sustainable-biotechnology-innovation 2025-11-07T01:21:32+00:00 hourly 0.9 https://trial.medpath.com/news/mark-cuban-s-cost-plus-drugs-adds-starjemza-biosimilar-to-specialty-medicine-portfolio 2025-11-07T01:21:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mark-cuban-s-cost-plus-drugs-adds-starjemza-biosimilar-to-specialty-medicine-portfolio 2025-11-07T01:21:17+00:00 hourly 0.9 https://trial.medpath.com/news/fda-505-b-2-pathway-drives-69-drug-reformulations-in-2024-2025-focusing-on-stability-and-patient-experience 2025-11-07T01:20:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-505-b-2-pathway-drives-69-drug-reformulations-in-2024-2025-focusing-on-stability-and-patient-experience 2025-11-07T01:20:45+00:00 hourly 0.9 https://trial.medpath.com/news/protagonist-therapeutics-advances-multiple-drug-programs-with-strong-financial-position-through-2028 2025-11-07T01:19:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protagonist-therapeutics-advances-multiple-drug-programs-with-strong-financial-position-through-2028 2025-11-07T01:19:48+00:00 hourly 0.9 https://trial.medpath.com/news/moffitt-researchers-develop-injectable-biomaterial-to-create-tumor-fighting-immune-structures 2025-11-07T01:18:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moffitt-researchers-develop-injectable-biomaterial-to-create-tumor-fighting-immune-structures 2025-11-07T01:18:27+00:00 hourly 0.9 https://trial.medpath.com/news/nchroma-bio-s-epigenetic-therapy-crma-1001-shows-promise-as-potential-functional-cure-for-chronic-hepatitis-b 2025-11-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nchroma-bio-s-epigenetic-therapy-crma-1001-shows-promise-as-potential-functional-cure-for-chronic-hepatitis-b 2025-11-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-leadership-turmoil-escalates-as-richard-pazdur-takes-cder-helm-amid-pfizer-novo-bidding-war 2025-11-06T21:41:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-leadership-turmoil-escalates-as-richard-pazdur-takes-cder-helm-amid-pfizer-novo-bidding-war 2025-11-06T21:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/cue-biopharma-and-immunoscape-partner-on-novel-seed-and-boost-cell-therapy-for-solid-tumors 2025-11-06T21:29:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cue-biopharma-and-immunoscape-partner-on-novel-seed-and-boost-cell-therapy-for-solid-tumors 2025-11-06T21:29:38+00:00 hourly 0.9 https://trial.medpath.com/news/genmab-reports-strong-q3-2025-results-with-key-pipeline-advances-and-8-billion-merus-acquisition 2025-11-06T21:27:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genmab-reports-strong-q3-2025-results-with-key-pipeline-advances-and-8-billion-merus-acquisition 2025-11-06T21:27:42+00:00 hourly 0.9 https://trial.medpath.com/news/revolutionary-protein-gel-successfully-regenerates-tooth-enamel-in-laboratory-tests 2025-11-06T21:27:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revolutionary-protein-gel-successfully-regenerates-tooth-enamel-in-laboratory-tests 2025-11-06T21:27:01+00:00 hourly 0.9 https://trial.medpath.com/news/gh-research-s-mebufotenin-therapy-gh001-shows-73-remission-rate-in-treatment-resistant-depression 2025-11-06T21:21:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gh-research-s-mebufotenin-therapy-gh001-shows-73-remission-rate-in-treatment-resistant-depression 2025-11-06T21:21:19+00:00 hourly 0.9 https://trial.medpath.com/news/rockefeller-scientists-engineer-next-generation-antibody-100-times-more-potent-than-ivig-for-autoimmune-diseases 2025-11-06T21:19:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rockefeller-scientists-engineer-next-generation-antibody-100-times-more-potent-than-ivig-for-autoimmune-diseases 2025-11-06T21:19:59+00:00 hourly 0.9 https://trial.medpath.com/news/cannformatics-receives-irb-approval-for-medical-cannabis-study-in-dementia-patients 2025-11-06T17:35:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cannformatics-receives-irb-approval-for-medical-cannabis-study-in-dementia-patients 2025-11-06T17:35:01+00:00 hourly 0.9 https://trial.medpath.com/news/axsome-therapeutics-acquires-novel-gaba-a-receptor-modulator-azd7325-for-epilepsy-treatment 2025-11-06T17:33:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/axsome-therapeutics-acquires-novel-gaba-a-receptor-modulator-azd7325-for-epilepsy-treatment 2025-11-06T17:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/chemomab-s-nebokitug-shows-sustained-anti-inflammatory-effects-in-48-week-psc-extension-study 2025-11-06T17:32:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chemomab-s-nebokitug-shows-sustained-anti-inflammatory-effects-in-48-week-psc-extension-study 2025-11-06T17:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/urteste-launches-european-clinical-trial-for-urine-based-pancreatic-cancer-detection-test 2025-11-06T17:29:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/urteste-launches-european-clinical-trial-for-urine-based-pancreatic-cancer-detection-test 2025-11-06T17:29:22+00:00 hourly 0.9 https://trial.medpath.com/news/black-diamond-therapeutics-prepares-to-release-phase-2-data-for-silevertinib-in-egfr-mutant-nsclc 2025-11-06T17:28:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/black-diamond-therapeutics-prepares-to-release-phase-2-data-for-silevertinib-in-egfr-mutant-nsclc 2025-11-06T17:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/biovectra-and-revolution-biomanufacturing-form-strategic-partnership-for-integrated-mrna-development-and-manufacturing 2025-11-06T17:25:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biovectra-and-revolution-biomanufacturing-form-strategic-partnership-for-integrated-mrna-development-and-manufacturing 2025-11-06T17:25:43+00:00 hourly 0.9 https://trial.medpath.com/news/elephas-biosciences-secures-40m-series-b-2-funding-to-launch-live-tumor-profiling-platform-for-immunotherapy-response-prediction 2025-11-06T17:24:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elephas-biosciences-secures-40m-series-b-2-funding-to-launch-live-tumor-profiling-platform-for-immunotherapy-response-prediction 2025-11-06T17:24:34+00:00 hourly 0.9 https://trial.medpath.com/news/ianalumab-ibrutinib-combination-enables-treatment-free-periods-for-chronic-lymphocytic-leukemia-patients 2025-11-06T17:24:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ianalumab-ibrutinib-combination-enables-treatment-free-periods-for-chronic-lymphocytic-leukemia-patients 2025-11-06T17:24:31+00:00 hourly 0.9 https://trial.medpath.com/news/pim3-inhibition-restores-car-t-cell-function-in-hypoxic-solid-tumors 2025-11-06T17:24:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pim3-inhibition-restores-car-t-cell-function-in-hypoxic-solid-tumors 2025-11-06T17:24:29+00:00 hourly 0.9 https://trial.medpath.com/news/medicenna-partners-with-italian-foundation-to-launch-neo-cyt-trial-testing-mdna11-in-high-risk-melanoma 2025-11-06T17:24:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicenna-partners-with-italian-foundation-to-launch-neo-cyt-trial-testing-mdna11-in-high-risk-melanoma 2025-11-06T17:24:26+00:00 hourly 0.9 https://trial.medpath.com/news/intranasal-h5n1-vaccine-shows-broad-immune-response-in-phase-i-trial 2025-11-06T17:22:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intranasal-h5n1-vaccine-shows-broad-immune-response-in-phase-i-trial 2025-11-06T17:22:58+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-acquires-sixpeaks-bio-for-300m-to-advance-muscle-preserving-obesity-treatments 2025-11-06T17:22:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-acquires-sixpeaks-bio-for-300m-to-advance-muscle-preserving-obesity-treatments 2025-11-06T17:22:49+00:00 hourly 0.9 https://trial.medpath.com/news/accipiter-biosciences-emerges-with-12-7m-seed-funding-to-develop-ai-designed-de-novo-protein-therapeutics 2025-11-06T17:22:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/accipiter-biosciences-emerges-with-12-7m-seed-funding-to-develop-ai-designed-de-novo-protein-therapeutics 2025-11-06T17:22:47+00:00 hourly 0.9 https://trial.medpath.com/news/palatin-advances-oral-mc4r-agonist-pl7737-for-obesity-treatment-with-promising-preclinical-data 2025-11-06T17:20:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/palatin-advances-oral-mc4r-agonist-pl7737-for-obesity-treatment-with-promising-preclinical-data 2025-11-06T17:20:37+00:00 hourly 0.9 https://trial.medpath.com/news/biomerica-expands-cdmo-services-to-capture-growing-diagnostic-development-market 2025-11-06T17:18:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomerica-expands-cdmo-services-to-capture-growing-diagnostic-development-market 2025-11-06T17:18:44+00:00 hourly 0.9 https://trial.medpath.com/news/debiopharm-completes-enrollment-for-first-ever-yearly-injectable-triptorelin-formulation-in-pediatric-central-precocious-puberty-trial 2025-11-06T17:18:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/debiopharm-completes-enrollment-for-first-ever-yearly-injectable-triptorelin-formulation-in-pediatric-central-precocious-puberty-trial 2025-11-06T17:18:20+00:00 hourly 0.9 https://trial.medpath.com/news/noema-pharma-s-cendifensine-shows-92-reduction-in-menopausal-hot-flashes-in-phase-2a-trial 2025-11-06T17:18:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/noema-pharma-s-cendifensine-shows-92-reduction-in-menopausal-hot-flashes-in-phase-2a-trial 2025-11-06T17:18:13+00:00 hourly 0.9 https://trial.medpath.com/news/montai-therapeutics-advances-first-in-class-oral-nrf2-agonist-for-ulcerative-colitis-to-ind-enabling-studies 2025-11-06T17:17:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/montai-therapeutics-advances-first-in-class-oral-nrf2-agonist-for-ulcerative-colitis-to-ind-enabling-studies 2025-11-06T17:17:59+00:00 hourly 0.9 https://trial.medpath.com/news/finerenone-shows-promise-as-first-new-type-1-diabetes-kidney-treatment-in-30-years 2025-11-06T17:17:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/finerenone-shows-promise-as-first-new-type-1-diabetes-kidney-treatment-in-30-years 2025-11-06T17:17:31+00:00 hourly 0.9 https://trial.medpath.com/news/caredx-launches-histomap-kidney-tissue-based-test-to-enhance-transplant-rejection-diagnosis 2025-11-06T17:17:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caredx-launches-histomap-kidney-tissue-based-test-to-enhance-transplant-rejection-diagnosis 2025-11-06T17:17:28+00:00 hourly 0.9 https://trial.medpath.com/news/sangamo-therapeutics-advances-fabry-disease-gene-therapy-toward-fda-submission-following-positive-clinical-data 2025-11-06T17:16:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sangamo-therapeutics-advances-fabry-disease-gene-therapy-toward-fda-submission-following-positive-clinical-data 2025-11-06T17:16:53+00:00 hourly 0.9 https://trial.medpath.com/news/who-releases-global-research-agenda-to-address-critical-gaps-in-pediatric-clinical-trials 2025-11-06T17:16:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/who-releases-global-research-agenda-to-address-critical-gaps-in-pediatric-clinical-trials 2025-11-06T17:16:42+00:00 hourly 0.9 https://trial.medpath.com/news/iavi-s-lassa-fever-vaccine-shows-promising-safety-and-immune-response-in-phase-1-trial 2025-11-06T17:16:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iavi-s-lassa-fever-vaccine-shows-promising-safety-and-immune-response-in-phase-1-trial 2025-11-06T17:16:32+00:00 hourly 0.9 https://trial.medpath.com/news/psyence-biomed-advances-phase-iib-psilocybin-trial-for-adjustment-disorder-in-palliative-care 2025-11-06T17:16:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/psyence-biomed-advances-phase-iib-psilocybin-trial-for-adjustment-disorder-in-palliative-care 2025-11-06T17:16:06+00:00 hourly 0.9 https://trial.medpath.com/news/mitochondrial-priming-emerges-as-key-determinant-for-car-t-nk-cell-immunosenolytic-therapy-success 2025-11-06T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mitochondrial-priming-emerges-as-key-determinant-for-car-t-nk-cell-immunosenolytic-therapy-success 2025-11-06T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3d-bioprinting-technology-advances-toward-clinical-translation-with-new-material-innovations-and-therapeutic-applications 2025-11-06T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/3d-bioprinting-technology-advances-toward-clinical-translation-with-new-material-innovations-and-therapeutic-applications 2025-11-06T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-shows-vibrant-system-delivers-sustained-relief-for-chronic-constipation-with-minimal-side-effects 2025-11-06T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-shows-vibrant-system-delivers-sustained-relief-for-chronic-constipation-with-minimal-side-effects 2025-11-06T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dual-breakthrough-studies-advance-stem-cell-based-bone-regeneration-for-spinal-fractures-and-bone-defects 2025-11-06T13:20:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dual-breakthrough-studies-advance-stem-cell-based-bone-regeneration-for-spinal-fractures-and-bone-defects 2025-11-06T13:20:51+00:00 hourly 0.9 https://trial.medpath.com/news/bright-minds-biosciences-launches-phase-2a-trial-for-novel-prader-willi-syndrome-treatment 2025-11-06T13:20:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bright-minds-biosciences-launches-phase-2a-trial-for-novel-prader-willi-syndrome-treatment 2025-11-06T13:20:45+00:00 hourly 0.9 https://trial.medpath.com/news/bioversys-initiates-phase-1-trial-of-bv100-in-china-targeting-critical-antimicrobial-resistance-crisis 2025-11-06T13:20:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioversys-initiates-phase-1-trial-of-bv100-in-china-targeting-critical-antimicrobial-resistance-crisis 2025-11-06T13:20:17+00:00 hourly 0.9 https://trial.medpath.com/news/celltrion-acquires-kaigene-s-novel-autoimmune-antibody-therapeutics-in-744-million-deal 2025-11-06T13:19:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celltrion-acquires-kaigene-s-novel-autoimmune-antibody-therapeutics-in-744-million-deal 2025-11-06T13:19:57+00:00 hourly 0.9 https://trial.medpath.com/news/arcoris-bio-raises-chf-6-3-million-to-advance-muse-nanotechnology-platform-for-digital-pathology 2025-11-06T13:19:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arcoris-bio-raises-chf-6-3-million-to-advance-muse-nanotechnology-platform-for-digital-pathology 2025-11-06T13:19:52+00:00 hourly 0.9 https://trial.medpath.com/news/zydus-receives-fda-orphan-drug-designation-for-desidustat-in-beta-thalassemia-treatment 2025-11-06T13:18:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zydus-receives-fda-orphan-drug-designation-for-desidustat-in-beta-thalassemia-treatment 2025-11-06T13:18:29+00:00 hourly 0.9 https://trial.medpath.com/news/new-zealand-introduces-fast-track-approval-amendments-to-accelerate-supermarket-development-and-reduce-healthcare-access-barriers 2025-11-06T13:18:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-zealand-introduces-fast-track-approval-amendments-to-accelerate-supermarket-development-and-reduce-healthcare-access-barriers 2025-11-06T13:18:27+00:00 hourly 0.9 https://trial.medpath.com/news/marksans-pharma-secures-uk-mhra-approval-for-exemestane-breast-cancer-treatment 2025-11-06T13:17:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/marksans-pharma-secures-uk-mhra-approval-for-exemestane-breast-cancer-treatment 2025-11-06T13:17:34+00:00 hourly 0.9 https://trial.medpath.com/news/nanotemper-acquires-envue-technologies-and-launches-dianthus-a-to-advance-single-molecule-drug-discovery 2025-11-06T13:17:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanotemper-acquires-envue-technologies-and-launches-dianthus-a-to-advance-single-molecule-drug-discovery 2025-11-06T13:17:04+00:00 hourly 0.9 https://trial.medpath.com/news/lungpacer-medical-initiates-stari-trial-for-next-generation-diaphragm-neurostimulation-in-critically-ill-patients 2025-11-06T09:19:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lungpacer-medical-initiates-stari-trial-for-next-generation-diaphragm-neurostimulation-in-critically-ill-patients 2025-11-06T09:19:11+00:00 hourly 0.9 https://trial.medpath.com/news/illuminare-biotechnologies-rizedisben-shows-promise-for-nerve-visualization-in-prostate-cancer-surgery 2025-11-06T09:19:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/illuminare-biotechnologies-rizedisben-shows-promise-for-nerve-visualization-in-prostate-cancer-surgery 2025-11-06T09:19:02+00:00 hourly 0.9 https://trial.medpath.com/news/rhythm-pharmaceuticals-secures-public-reimbursement-for-imcivree-in-five-canadian-provinces 2025-11-06T09:18:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rhythm-pharmaceuticals-secures-public-reimbursement-for-imcivree-in-five-canadian-provinces 2025-11-06T09:18:54+00:00 hourly 0.9 https://trial.medpath.com/news/mwyngil-therapeutics-licenses-gpr75-modulators-for-novel-obesity-and-diabetes-treatment-approach 2025-11-06T04:03:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mwyngil-therapeutics-licenses-gpr75-modulators-for-novel-obesity-and-diabetes-treatment-approach 2025-11-06T04:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-18-warning-letters-to-companies-illegally-marketing-unapproved-botulinum-toxin-products 2025-11-06T01:42:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-18-warning-letters-to-companies-illegally-marketing-unapproved-botulinum-toxin-products 2025-11-06T01:42:39+00:00 hourly 0.9 https://trial.medpath.com/news/gossamer-bio-advances-seralutinib-phase-3-trials-with-prosera-results-expected-february-2026 2025-11-06T01:40:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gossamer-bio-advances-seralutinib-phase-3-trials-with-prosera-results-expected-february-2026 2025-11-06T01:40:58+00:00 hourly 0.9 https://trial.medpath.com/news/dynavax-secures-exclusive-license-to-vaxart-s-oral-covid-19-vaccine-in-25-million-deal 2025-11-06T01:37:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dynavax-secures-exclusive-license-to-vaxart-s-oral-covid-19-vaccine-in-25-million-deal 2025-11-06T01:37:07+00:00 hourly 0.9 https://trial.medpath.com/news/lumonus-secures-a-25-million-series-b-to-expand-ai-powered-radiation-oncology-platform-globally 2025-11-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lumonus-secures-a-25-million-series-b-to-expand-ai-powered-radiation-oncology-platform-globally 2025-11-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-bioepis-secures-japanese-approval-for-ustekinumab-biosimilar-expands-global-autoimmune-treatment-access 2025-11-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samsung-bioepis-secures-japanese-approval-for-ustekinumab-biosimilar-expands-global-autoimmune-treatment-access 2025-11-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/foghorn-therapeutics-advances-multi-target-protein-degrader-pipeline-with-fhd-909-phase-1-trial-progressing 2025-11-05T22:59:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/foghorn-therapeutics-advances-multi-target-protein-degrader-pipeline-with-fhd-909-phase-1-trial-progressing 2025-11-05T22:59:06+00:00 hourly 0.9 https://trial.medpath.com/news/next-oncology-expands-phase-i-cancer-trial-network-to-japan-through-kansai-medical-university-partnership 2025-11-05T22:53:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/next-oncology-expands-phase-i-cancer-trial-network-to-japan-through-kansai-medical-university-partnership 2025-11-05T22:53:27+00:00 hourly 0.9 https://trial.medpath.com/news/processa-pharmaceuticals-to-present-adaptive-phase-2-3-study-of-pcs499-for-rare-kidney-disease-fsgs-at-asn-kidney-week-2025 2025-11-05T22:53:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/processa-pharmaceuticals-to-present-adaptive-phase-2-3-study-of-pcs499-for-rare-kidney-disease-fsgs-at-asn-kidney-week-2025 2025-11-05T22:53:22+00:00 hourly 0.9 https://trial.medpath.com/news/avant-technologies-and-sgaustria-launch-joint-venture-to-develop-stem-cell-based-diabetes-therapy 2025-11-05T22:51:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avant-technologies-and-sgaustria-launch-joint-venture-to-develop-stem-cell-based-diabetes-therapy 2025-11-05T22:51:46+00:00 hourly 0.9 https://trial.medpath.com/news/normunity-doses-first-patient-with-novel-t-cell-engager-nrm-823-in-phase-1-solid-tumor-trial 2025-11-05T22:51:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/normunity-doses-first-patient-with-novel-t-cell-engager-nrm-823-in-phase-1-solid-tumor-trial 2025-11-05T22:51:16+00:00 hourly 0.9 https://trial.medpath.com/news/immune-checkpoint-inhibitors-demonstrate-safety-and-efficacy-for-nsclc-treatment-in-hiv-positive-patients 2025-11-05T22:50:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immune-checkpoint-inhibitors-demonstrate-safety-and-efficacy-for-nsclc-treatment-in-hiv-positive-patients 2025-11-05T22:50:39+00:00 hourly 0.9 https://trial.medpath.com/news/palvella-therapeutics-announces-qtorin-pitavastatin-for-rare-skin-disease-dsap-with-no-current-fda-approved-treatments 2025-11-05T22:49:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/palvella-therapeutics-announces-qtorin-pitavastatin-for-rare-skin-disease-dsap-with-no-current-fda-approved-treatments 2025-11-05T22:49:54+00:00 hourly 0.9 https://trial.medpath.com/news/sonothera-demonstrates-novel-ultrasound-gene-delivery-for-x-linked-alport-syndrome-treatment 2025-11-05T22:48:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sonothera-demonstrates-novel-ultrasound-gene-delivery-for-x-linked-alport-syndrome-treatment 2025-11-05T22:48:38+00:00 hourly 0.9 https://trial.medpath.com/news/touchlight-expands-mbdna-platform-with-three-new-circular-dna-architectures-for-gene-therapy 2025-11-05T22:48:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/touchlight-expands-mbdna-platform-with-three-new-circular-dna-architectures-for-gene-therapy 2025-11-05T22:48:34+00:00 hourly 0.9 https://trial.medpath.com/news/ai-achieves-atomic-precision-in-antibody-design-revolutionizing-drug-discovery 2025-11-05T22:48:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-achieves-atomic-precision-in-antibody-design-revolutionizing-drug-discovery 2025-11-05T22:48:19+00:00 hourly 0.9 https://trial.medpath.com/news/lunai-bioworks-ai-platform-achieves-94-accuracy-in-neurotoxic-compound-detection-using-zebrafish-models 2025-11-05T22:45:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lunai-bioworks-ai-platform-achieves-94-accuracy-in-neurotoxic-compound-detection-using-zebrafish-models 2025-11-05T22:45:17+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-pediatric-treatment-for-irritable-bowel-syndrome-with-constipation 2025-11-05T22:44:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-pediatric-treatment-for-irritable-bowel-syndrome-with-constipation 2025-11-05T22:44:01+00:00 hourly 0.9 https://trial.medpath.com/news/sotio-s-sot106-adc-shows-promise-in-sarcoma-treatment-with-strong-preclinical-results 2025-11-05T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sotio-s-sot106-adc-shows-promise-in-sarcoma-treatment-with-strong-preclinical-results 2025-11-05T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ananda-scientific-partners-with-benta-to-advance-ptsd-treatment-development-in-europe-and-mena 2025-11-05T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ananda-scientific-partners-with-benta-to-advance-ptsd-treatment-development-in-europe-and-mena 2025-11-05T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-researchers-discover-nicotinamide-s-cardioprotective-effect-against-pd-1-inhibitor-toxicity 2025-11-05T21:52:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chinese-researchers-discover-nicotinamide-s-cardioprotective-effect-against-pd-1-inhibitor-toxicity 2025-11-05T21:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/pacbio-hifi-sequencing-achieves-100-detection-rate-for-pathogenic-variants-in-multi-center-clinical-study 2025-11-05T17:50:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pacbio-hifi-sequencing-achieves-100-detection-rate-for-pathogenic-variants-in-multi-center-clinical-study 2025-11-05T17:50:38+00:00 hourly 0.9 https://trial.medpath.com/news/moberg-pharma-partners-with-karo-healthcare-to-launch-breakthrough-topical-nail-fungus-treatment-across-europe 2025-11-05T17:48:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moberg-pharma-partners-with-karo-healthcare-to-launch-breakthrough-topical-nail-fungus-treatment-across-europe 2025-11-05T17:48:59+00:00 hourly 0.9 https://trial.medpath.com/news/phase-1-trial-shows-ppv-06-vaccine-safely-targets-il-6-in-knee-osteoarthritis 2025-11-05T17:44:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-1-trial-shows-ppv-06-vaccine-safely-targets-il-6-in-knee-osteoarthritis 2025-11-05T17:44:27+00:00 hourly 0.9 https://trial.medpath.com/news/jupiter-neurosciences-receives-fda-ind-clearance-for-jotrol-phase-2a-trial-in-parkinson-s-disease 2025-11-05T17:43:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jupiter-neurosciences-receives-fda-ind-clearance-for-jotrol-phase-2a-trial-in-parkinson-s-disease 2025-11-05T17:43:58+00:00 hourly 0.9 https://trial.medpath.com/news/verismo-therapeutics-novel-kir-car-platform-shows-enhanced-safety-and-efficacy-in-solid-tumor-preclinical-studies 2025-11-05T17:43:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verismo-therapeutics-novel-kir-car-platform-shows-enhanced-safety-and-efficacy-in-solid-tumor-preclinical-studies 2025-11-05T17:43:54+00:00 hourly 0.9 https://trial.medpath.com/news/maat-pharma-s-maat034-shows-83-7-tumor-growth-reduction-in-preclinical-studies-at-sitc-2025 2025-11-05T17:43:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maat-pharma-s-maat034-shows-83-7-tumor-growth-reduction-in-preclinical-studies-at-sitc-2025 2025-11-05T17:43:51+00:00 hourly 0.9 https://trial.medpath.com/news/nona-biosciences-expands-car-t-partnership-with-umoja-biopharma-to-develop-in-vivo-cell-therapies 2025-11-05T17:43:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nona-biosciences-expands-car-t-partnership-with-umoja-biopharma-to-develop-in-vivo-cell-therapies 2025-11-05T17:43:23+00:00 hourly 0.9 https://trial.medpath.com/news/india-launches-world-s-first-humanized-car-t-therapy-nexcar19-for-cancer-treatment 2025-11-05T17:43:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-launches-world-s-first-humanized-car-t-therapy-nexcar19-for-cancer-treatment 2025-11-05T17:43:20+00:00 hourly 0.9 https://trial.medpath.com/news/tennessee-oncology-launches-dedicated-early-phase-clinical-research-unit-to-expand-community-access-to-experimental-cancer-therapies 2025-11-05T17:42:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tennessee-oncology-launches-dedicated-early-phase-clinical-research-unit-to-expand-community-access-to-experimental-cancer-therapies 2025-11-05T17:42:26+00:00 hourly 0.9 https://trial.medpath.com/news/biomarker-partnerships-surge-as-precision-medicine-drives-strategic-collaborations 2025-11-05T17:42:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomarker-partnerships-surge-as-precision-medicine-drives-strategic-collaborations 2025-11-05T17:42:04+00:00 hourly 0.9 https://trial.medpath.com/news/tenpoint-therapeutics-submits-first-international-nda-for-brimochol-pf-presbyopia-treatment-in-south-korea 2025-11-05T17:41:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tenpoint-therapeutics-submits-first-international-nda-for-brimochol-pf-presbyopia-treatment-in-south-korea 2025-11-05T17:41:44+00:00 hourly 0.9 https://trial.medpath.com/news/jaya-biosciences-secures-u-s-patent-for-gene-therapy-approach-to-alzheimer-s-disease-treatment 2025-11-05T17:41:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jaya-biosciences-secures-u-s-patent-for-gene-therapy-approach-to-alzheimer-s-disease-treatment 2025-11-05T17:41:40+00:00 hourly 0.9 https://trial.medpath.com/news/world-s-first-egfr-targeted-adc-receives-approval-in-china-for-nasopharyngeal-carcinoma 2025-11-05T17:40:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-s-first-egfr-targeted-adc-receives-approval-in-china-for-nasopharyngeal-carcinoma 2025-11-05T17:40:35+00:00 hourly 0.9 https://trial.medpath.com/news/recursion-achieves-500m-partnership-milestone-with-novel-microglial-cell-map-for-neurological-disease-research 2025-11-05T17:40:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recursion-achieves-500m-partnership-milestone-with-novel-microglial-cell-map-for-neurological-disease-research 2025-11-05T17:40:31+00:00 hourly 0.9 https://trial.medpath.com/news/atea-pharmaceuticals-advances-hcv-phase-3-program-with-new-dual-mechanism-data-and-expands-pipeline-to-hepatitis-e 2025-11-05T17:40:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atea-pharmaceuticals-advances-hcv-phase-3-program-with-new-dual-mechanism-data-and-expands-pipeline-to-hepatitis-e 2025-11-05T17:40:28+00:00 hourly 0.9 https://trial.medpath.com/news/recursion-appoints-new-ceo-as-ai-drug-discovery-pioneer-faces-market-pressures 2025-11-05T17:39:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recursion-appoints-new-ceo-as-ai-drug-discovery-pioneer-faces-market-pressures 2025-11-05T17:39:42+00:00 hourly 0.9 https://trial.medpath.com/news/anika-therapeutics-submits-final-pma-module-for-hyalofast-cartilage-repair-scaffold-despite-mixed-phase-iii-results 2025-11-05T17:39:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anika-therapeutics-submits-final-pma-module-for-hyalofast-cartilage-repair-scaffold-despite-mixed-phase-iii-results 2025-11-05T17:39:18+00:00 hourly 0.9 https://trial.medpath.com/news/polyactiva-and-raresight-partner-to-develop-first-in-class-treatments-for-rare-pediatric-retinal-diseases 2025-11-05T17:38:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/polyactiva-and-raresight-partner-to-develop-first-in-class-treatments-for-rare-pediatric-retinal-diseases 2025-11-05T17:38:24+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-ever-robotic-microsurgical-study-for-alzheimer-s-disease-treatment 2025-11-05T17:38:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-ever-robotic-microsurgical-study-for-alzheimer-s-disease-treatment 2025-11-05T17:38:21+00:00 hourly 0.9 https://trial.medpath.com/news/lunai-bioworks-reports-complete-tumor-regression-with-second-generation-dendritic-cell-therapy-in-pancreatic-cancer-models 2025-11-05T17:37:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lunai-bioworks-reports-complete-tumor-regression-with-second-generation-dendritic-cell-therapy-in-pancreatic-cancer-models 2025-11-05T17:37:42+00:00 hourly 0.9 https://trial.medpath.com/news/st-jude-scientists-develop-risk-stratification-system-to-reduce-medulloblastoma-treatment-toxicity 2025-11-05T17:37:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/st-jude-scientists-develop-risk-stratification-system-to-reduce-medulloblastoma-treatment-toxicity 2025-11-05T17:37:04+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-vyvgart-sc-as-first-novel-cidp-treatment-in-three-decades 2025-11-05T16:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-approves-vyvgart-sc-as-first-novel-cidp-treatment-in-three-decades 2025-11-05T16:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/victor-trial-shows-neutral-primary-outcome-for-vericiguat-in-stable-heart-failure-patients 2025-11-05T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/victor-trial-shows-neutral-primary-outcome-for-vericiguat-in-stable-heart-failure-patients 2025-11-05T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/moonlake-s-sonelokimab-shows-promise-in-palmoplantar-pustulosis-phase-2-trial-advances-toward-bla-submission 2025-11-05T14:52:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moonlake-s-sonelokimab-shows-promise-in-palmoplantar-pustulosis-phase-2-trial-advances-toward-bla-submission 2025-11-05T14:52:27+00:00 hourly 0.9 https://trial.medpath.com/news/recursion-pharmaceuticals-names-najat-khan-as-new-ceo-in-leadership-transition 2025-11-05T14:51:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recursion-pharmaceuticals-names-najat-khan-as-new-ceo-in-leadership-transition 2025-11-05T14:51:13+00:00 hourly 0.9 https://trial.medpath.com/news/pre-treatment-lung-abnormalities-emerge-as-major-risk-factor-for-t-dxd-pneumonitis-in-metastatic-breast-cancer 2025-11-05T14:48:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pre-treatment-lung-abnormalities-emerge-as-major-risk-factor-for-t-dxd-pneumonitis-in-metastatic-breast-cancer 2025-11-05T14:48:02+00:00 hourly 0.9 https://trial.medpath.com/news/lift-biosciences-unveils-promising-preclinical-data-for-first-in-class-neutrophil-cell-therapy-at-sitc-2025 2025-11-05T14:45:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lift-biosciences-unveils-promising-preclinical-data-for-first-in-class-neutrophil-cell-therapy-at-sitc-2025 2025-11-05T14:45:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-leukogene-s-m2t-cd33-for-acute-myeloid-leukemia-treatment 2025-11-05T14:44:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-leukogene-s-m2t-cd33-for-acute-myeloid-leukemia-treatment 2025-11-05T14:44:03+00:00 hourly 0.9 https://trial.medpath.com/news/cellbxhealth-demonstrates-compatibility-between-parsortix-platform-and-roche-s-automated-staining-system-for-adc-target-analysis 2025-11-05T10:39:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellbxhealth-demonstrates-compatibility-between-parsortix-platform-and-roche-s-automated-staining-system-for-adc-target-analysis 2025-11-05T10:39:32+00:00 hourly 0.9 https://trial.medpath.com/news/biomea-fusion-reports-sustained-diabetes-efficacy-with-icovamenib-and-advances-obesity-pipeline-with-bmf-650 2025-11-05T10:38:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomea-fusion-reports-sustained-diabetes-efficacy-with-icovamenib-and-advances-obesity-pipeline-with-bmf-650 2025-11-05T10:38:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-restylane-lyft-for-chin-enhancement-expanding-hyaluronic-acid-filler-applications 2025-11-05T10:37:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-restylane-lyft-for-chin-enhancement-expanding-hyaluronic-acid-filler-applications 2025-11-05T10:37:58+00:00 hourly 0.9 https://trial.medpath.com/news/icr-researchers-develop-novel-formulation-strategies-to-enable-oral-delivery-of-vhl-based-protacs 2025-11-05T05:57:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/icr-researchers-develop-novel-formulation-strategies-to-enable-oral-delivery-of-vhl-based-protacs 2025-11-05T05:57:00+00:00 hourly 0.9 https://trial.medpath.com/news/mesoblast-secures-fda-meeting-to-discuss-opioid-cessation-data-for-chronic-back-pain-cell-therapy 2025-11-05T05:25:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mesoblast-secures-fda-meeting-to-discuss-opioid-cessation-data-for-chronic-back-pain-cell-therapy 2025-11-05T05:25:42+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-s-shockwave-ivl-system-demonstrates-strong-one-year-outcomes-in-complex-peripheral-artery-disease-treatment 2025-11-05T05:25:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-s-shockwave-ivl-system-demonstrates-strong-one-year-outcomes-in-complex-peripheral-artery-disease-treatment 2025-11-05T05:25:13+00:00 hourly 0.9 https://trial.medpath.com/news/large-scale-uk-study-shows-covid-19-infection-poses-greater-heart-risk-to-children-than-vaccination 2025-11-05T05:24:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/large-scale-uk-study-shows-covid-19-infection-poses-greater-heart-risk-to-children-than-vaccination 2025-11-05T05:24:38+00:00 hourly 0.9 https://trial.medpath.com/news/colossal-biosciences-acquires-leading-animal-cloning-company-viagen-to-advance-de-extinction-platform 2025-11-05T05:22:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/colossal-biosciences-acquires-leading-animal-cloning-company-viagen-to-advance-de-extinction-platform 2025-11-05T05:22:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-complete-response-letter-for-biohaven-s-vyglxia-troriluzole-for-spinocerebellar-ataxia 2025-11-05T05:22:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-complete-response-letter-for-biohaven-s-vyglxia-troriluzole-for-spinocerebellar-ataxia 2025-11-05T05:22:09+00:00 hourly 0.9 https://trial.medpath.com/news/renerve-expands-clinical-trial-for-fda-cleared-nervalign-nerve-cuff-following-positive-interim-results 2025-11-05T05:22:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/renerve-expands-clinical-trial-for-fda-cleared-nervalign-nerve-cuff-following-positive-interim-results 2025-11-05T05:22:04+00:00 hourly 0.9 https://trial.medpath.com/news/relmada-therapeutics-raises-100-million-to-advance-oncology-and-cns-pipeline 2025-11-05T01:26:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/relmada-therapeutics-raises-100-million-to-advance-oncology-and-cns-pipeline 2025-11-05T01:26:27+00:00 hourly 0.9 https://trial.medpath.com/news/qol-medical-to-acquire-evoke-pharma-for-11-per-share-securing-gimoti-nasal-spray-for-diabetic-gastroparesis 2025-11-05T01:24:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qol-medical-to-acquire-evoke-pharma-for-11-per-share-securing-gimoti-nasal-spray-for-diabetic-gastroparesis 2025-11-05T01:24:29+00:00 hourly 0.9 https://trial.medpath.com/news/bullfrog-ai-s-precision-oncology-platform-identifies-patient-subtypes-for-enhanced-glufosfamide-response-in-pancreatic-cancer 2025-11-05T01:23:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bullfrog-ai-s-precision-oncology-platform-identifies-patient-subtypes-for-enhanced-glufosfamide-response-in-pancreatic-cancer 2025-11-05T01:23:18+00:00 hourly 0.9 https://trial.medpath.com/news/pretzel-therapeutics-unveils-polrmt-as-novel-obesity-target-with-promising-preclinical-results 2025-11-05T01:22:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pretzel-therapeutics-unveils-polrmt-as-novel-obesity-target-with-promising-preclinical-results 2025-11-05T01:22:22+00:00 hourly 0.9 https://trial.medpath.com/news/eilean-therapeutics-first-in-class-malt1-degrader-te205-shows-promising-efficacy-in-ulcerative-colitis-preclinical-studies 2025-11-05T01:21:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eilean-therapeutics-first-in-class-malt1-degrader-te205-shows-promising-efficacy-in-ulcerative-colitis-preclinical-studies 2025-11-05T01:21:05+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-trial-shows-stem-cell-therapy-reduces-heart-failure-risk-by-57-after-heart-attack 2025-11-05T01:20:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-trial-shows-stem-cell-therapy-reduces-heart-failure-risk-by-57-after-heart-attack 2025-11-05T01:20:17+00:00 hourly 0.9 https://trial.medpath.com/news/metavia-s-da-1726-shows-promising-weight-loss-results-in-phase-1-trial-with-superior-lipid-benefits 2025-11-05T01:19:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metavia-s-da-1726-shows-promising-weight-loss-results-in-phase-1-trial-with-superior-lipid-benefits 2025-11-05T01:19:49+00:00 hourly 0.9 https://trial.medpath.com/news/arena-bioworks-shuts-down-after-less-than-two-years-citing-policy-uncertainty-and-funding-challenges 2025-11-05T01:17:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arena-bioworks-shuts-down-after-less-than-two-years-citing-policy-uncertainty-and-funding-challenges 2025-11-05T01:17:55+00:00 hourly 0.9 https://trial.medpath.com/news/first-ras-inhibitor-shows-clinical-promise-for-nras-mutant-melanoma-patients 2025-11-05T01:17:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-ras-inhibitor-shows-clinical-promise-for-nras-mutant-melanoma-patients 2025-11-05T01:17:32+00:00 hourly 0.9 https://trial.medpath.com/news/stoke-therapeutics-advances-phase-3-dravet-syndrome-trial-with-strong-financial-position-through-2028 2025-11-05T01:17:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stoke-therapeutics-advances-phase-3-dravet-syndrome-trial-with-strong-financial-position-through-2028 2025-11-05T01:17:26+00:00 hourly 0.9 https://trial.medpath.com/news/memorial-sloan-kettering-and-yale-cancer-center-deploy-triomics-ai-platform-to-accelerate-clinical-trial-matching 2025-11-05T01:16:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/memorial-sloan-kettering-and-yale-cancer-center-deploy-triomics-ai-platform-to-accelerate-clinical-trial-matching 2025-11-05T01:16:13+00:00 hourly 0.9 https://trial.medpath.com/news/corvus-pharmaceuticals-reports-promising-phase-1-1b-results-for-soquelitinib-in-t-cell-lymphoma-at-ash-2025 2025-11-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/corvus-pharmaceuticals-reports-promising-phase-1-1b-results-for-soquelitinib-in-t-cell-lymphoma-at-ash-2025 2025-11-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/doxycycline-shows-30-35-reduction-in-schizophrenia-risk-among-finnish-adolescents 2025-11-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/doxycycline-shows-30-35-reduction-in-schizophrenia-risk-among-finnish-adolescents 2025-11-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/largest-wearable-defibrillator-study-demonstrates-100-conversion-success-in-21612-patients 2025-11-04T21:25:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/largest-wearable-defibrillator-study-demonstrates-100-conversion-success-in-21612-patients 2025-11-04T21:25:38+00:00 hourly 0.9 https://trial.medpath.com/news/pacira-biosciences-licenses-novel-long-acting-ropivacaine-formulation-amt-143-for-postsurgical-pain-management 2025-11-04T21:25:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pacira-biosciences-licenses-novel-long-acting-ropivacaine-formulation-amt-143-for-postsurgical-pain-management 2025-11-04T21:25:32+00:00 hourly 0.9 https://trial.medpath.com/news/aveo-oncology-partners-with-hibercell-to-develop-first-in-human-perk-inhibitor-for-renal-cell-carcinoma 2025-11-04T21:23:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aveo-oncology-partners-with-hibercell-to-develop-first-in-human-perk-inhibitor-for-renal-cell-carcinoma 2025-11-04T21:23:57+00:00 hourly 0.9 https://trial.medpath.com/news/intrepid-alliance-launches-open-access-antiviral-toolbox-to-address-global-r-d-gaps 2025-11-04T21:22:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intrepid-alliance-launches-open-access-antiviral-toolbox-to-address-global-r-d-gaps 2025-11-04T21:22:55+00:00 hourly 0.9 https://trial.medpath.com/news/scilex-secures-10m-exclusive-license-for-ai-driven-biotech-asset-tokenization-platform 2025-11-04T21:22:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scilex-secures-10m-exclusive-license-for-ai-driven-biotech-asset-tokenization-platform 2025-11-04T21:22:10+00:00 hourly 0.9 https://trial.medpath.com/news/ankyra-therapeutics-initiates-phase-1b-trial-of-anchored-il-12-immunotherapy-combined-with-checkpoint-blockade-in-lung-cancer 2025-11-04T21:21:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ankyra-therapeutics-initiates-phase-1b-trial-of-anchored-il-12-immunotherapy-combined-with-checkpoint-blockade-in-lung-cancer 2025-11-04T21:21:37+00:00 hourly 0.9 https://trial.medpath.com/news/five-year-zuma-5-data-shows-axicabtagene-ciloleucel-achieves-durable-responses-in-relapsed-refractory-indolent-non-hodgkin-lymphoma 2025-11-04T21:21:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/five-year-zuma-5-data-shows-axicabtagene-ciloleucel-achieves-durable-responses-in-relapsed-refractory-indolent-non-hodgkin-lymphoma 2025-11-04T21:21:30+00:00 hourly 0.9 https://trial.medpath.com/news/storm-pe-trial-shows-mechanical-thrombectomy-superior-to-anticoagulation-alone-for-pulmonary-embolism 2025-11-04T21:20:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/storm-pe-trial-shows-mechanical-thrombectomy-superior-to-anticoagulation-alone-for-pulmonary-embolism 2025-11-04T21:20:07+00:00 hourly 0.9 https://trial.medpath.com/news/defence-therapeutics-accum-kadcyla-shows-20-fold-efficacy-boost-in-her2-positive-breast-cancer-models 2025-11-04T21:19:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/defence-therapeutics-accum-kadcyla-shows-20-fold-efficacy-boost-in-her2-positive-breast-cancer-models 2025-11-04T21:19:19+00:00 hourly 0.9 https://trial.medpath.com/news/qiagen-acquires-parse-biosciences-for-225-million-to-expand-single-cell-analysis-capabilities 2025-11-04T21:18:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qiagen-acquires-parse-biosciences-for-225-million-to-expand-single-cell-analysis-capabilities 2025-11-04T21:18:28+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-secures-570m-licensing-deal-for-cdr111-trispecific-t-cell-engager-targeting-autoimmune-diseases 2025-11-04T21:17:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boehringer-ingelheim-secures-570m-licensing-deal-for-cdr111-trispecific-t-cell-engager-targeting-autoimmune-diseases 2025-11-04T21:17:48+00:00 hourly 0.9 https://trial.medpath.com/news/aqua-medical-receives-fda-ide-approval-for-breakthrough-endoscopic-type-2-diabetes-treatment 2025-11-04T21:17:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aqua-medical-receives-fda-ide-approval-for-breakthrough-endoscopic-type-2-diabetes-treatment 2025-11-04T21:17:41+00:00 hourly 0.9 https://trial.medpath.com/news/castle-biosciences-launches-advancead-tx-gene-expression-test-to-guide-atopic-dermatitis-treatment-selection 2025-11-04T21:17:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/castle-biosciences-launches-advancead-tx-gene-expression-test-to-guide-atopic-dermatitis-treatment-selection 2025-11-04T21:17:33+00:00 hourly 0.9 https://trial.medpath.com/news/hims-hers-and-novo-nordisk-in-talks-for-wegovy-distribution-partnership 2025-11-04T21:17:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hims-hers-and-novo-nordisk-in-talks-for-wegovy-distribution-partnership 2025-11-04T21:17:21+00:00 hourly 0.9 https://trial.medpath.com/news/eva-pharma-launches-major-cancer-drug-manufacturing-facility-in-egypt-to-address-growing-oncology-burden 2025-11-04T21:16:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eva-pharma-launches-major-cancer-drug-manufacturing-facility-in-egypt-to-address-growing-oncology-burden 2025-11-04T21:16:33+00:00 hourly 0.9 https://trial.medpath.com/news/chiesi-discontinues-copd-drug-tanimilast-after-phase-iii-trial-failure 2025-11-04T21:16:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chiesi-discontinues-copd-drug-tanimilast-after-phase-iii-trial-failure 2025-11-04T21:16:06+00:00 hourly 0.9 https://trial.medpath.com/news/biovac-opens-advanced-vaccine-development-laboratory-in-cape-town-to-strengthen-africa-s-manufacturing-independence 2025-11-04T17:28:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biovac-opens-advanced-vaccine-development-laboratory-in-cape-town-to-strengthen-africa-s-manufacturing-independence 2025-11-04T17:28:25+00:00 hourly 0.9 https://trial.medpath.com/news/kamada-initiates-shield-trial-to-prevent-late-cmv-infection-in-high-risk-kidney-transplant-recipients 2025-11-04T17:26:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kamada-initiates-shield-trial-to-prevent-late-cmv-infection-in-high-risk-kidney-transplant-recipients 2025-11-04T17:26:45+00:00 hourly 0.9 https://trial.medpath.com/news/alkem-foundation-partners-with-iit-bombay-to-establish-india-s-first-immunotherapy-research-centre 2025-11-04T17:26:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alkem-foundation-partners-with-iit-bombay-to-establish-india-s-first-immunotherapy-research-centre 2025-11-04T17:26:34+00:00 hourly 0.9 https://trial.medpath.com/news/pacbio-s-sequel-ii-cndx-becomes-world-s-first-clinically-approved-long-read-sequencer-in-china 2025-11-04T17:25:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pacbio-s-sequel-ii-cndx-becomes-world-s-first-clinically-approved-long-read-sequencer-in-china 2025-11-04T17:25:53+00:00 hourly 0.9 https://trial.medpath.com/news/reset-trial-shows-sprint-pns-delivers-superior-pain-relief-for-chronic-low-back-pain-compared-to-standard-care 2025-11-04T17:25:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/reset-trial-shows-sprint-pns-delivers-superior-pain-relief-for-chronic-low-back-pain-compared-to-standard-care 2025-11-04T17:25:11+00:00 hourly 0.9 https://trial.medpath.com/news/castlevax-initiates-phase-2-trial-of-intranasal-covid-19-vaccine-targeting-mucosal-immunity 2025-11-04T17:25:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/castlevax-initiates-phase-2-trial-of-intranasal-covid-19-vaccine-targeting-mucosal-immunity 2025-11-04T17:25:09+00:00 hourly 0.9 https://trial.medpath.com/news/azalea-therapeutics-launches-with-82-million-to-pioneer-in-vivo-car-t-cell-engineering 2025-11-04T17:23:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/azalea-therapeutics-launches-with-82-million-to-pioneer-in-vivo-car-t-cell-engineering 2025-11-04T17:23:16+00:00 hourly 0.9 https://trial.medpath.com/news/grit-biotherapeutics-in-vivo-car-t-therapy-gt801-selected-for-oral-presentation-at-ash-2025 2025-11-04T17:23:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/grit-biotherapeutics-in-vivo-car-t-therapy-gt801-selected-for-oral-presentation-at-ash-2025 2025-11-04T17:23:08+00:00 hourly 0.9 https://trial.medpath.com/news/royalty-pharma-acquires-310-million-amvuttra-royalty-interest-from-blackstone-life-sciences 2025-11-04T17:22:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/royalty-pharma-acquires-310-million-amvuttra-royalty-interest-from-blackstone-life-sciences 2025-11-04T17:22:55+00:00 hourly 0.9 https://trial.medpath.com/news/cytomx-reports-promising-phase-1-biomarker-data-for-cx-801-in-advanced-melanoma-at-sitc-2025 2025-11-04T17:21:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytomx-reports-promising-phase-1-biomarker-data-for-cx-801-in-advanced-melanoma-at-sitc-2025 2025-11-04T17:21:23+00:00 hourly 0.9 https://trial.medpath.com/news/ignite-biomedical-and-liquid-biosciences-discover-ai-driven-biomarkers-for-autism-spectrum-disorder-diagnosis-and-treatment 2025-11-04T17:21:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ignite-biomedical-and-liquid-biosciences-discover-ai-driven-biomarkers-for-autism-spectrum-disorder-diagnosis-and-treatment 2025-11-04T17:21:21+00:00 hourly 0.9 https://trial.medpath.com/news/crescent-biopharma-s-cr-001-bispecific-antibody-shows-cooperative-pharmacology-in-preclinical-studies 2025-11-04T17:21:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crescent-biopharma-s-cr-001-bispecific-antibody-shows-cooperative-pharmacology-in-preclinical-studies 2025-11-04T17:21:09+00:00 hourly 0.9 https://trial.medpath.com/news/britecyte-receives-1m-maryland-grant-to-advance-novel-adipose-tissue-therapy-for-osteoarthritis 2025-11-04T17:21:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/britecyte-receives-1m-maryland-grant-to-advance-novel-adipose-tissue-therapy-for-osteoarthritis 2025-11-04T17:21:07+00:00 hourly 0.9 https://trial.medpath.com/news/basilea-receives-30-million-milestone-payment-as-cresemba-antifungal-sales-surge-27-globally 2025-11-04T17:19:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/basilea-receives-30-million-milestone-payment-as-cresemba-antifungal-sales-surge-27-globally 2025-11-04T17:19:07+00:00 hourly 0.9 https://trial.medpath.com/news/medunik-usa-expands-medicaid-coverage-for-pheburane-in-rare-disease-treatment-access-initiative 2025-11-04T17:19:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medunik-usa-expands-medicaid-coverage-for-pheburane-in-rare-disease-treatment-access-initiative 2025-11-04T17:19:05+00:00 hourly 0.9 https://trial.medpath.com/news/expert-consensus-validates-clinical-potential-of-circulating-tumor-cells-highlights-parsortix-platform-as-leading-technology 2025-11-04T17:18:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/expert-consensus-validates-clinical-potential-of-circulating-tumor-cells-highlights-parsortix-platform-as-leading-technology 2025-11-04T17:18:49+00:00 hourly 0.9 https://trial.medpath.com/news/phenomix-sciences-validates-myphenome-test-for-predicting-glp-1-response-across-diverse-patient-populations 2025-11-04T17:17:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phenomix-sciences-validates-myphenome-test-for-predicting-glp-1-response-across-diverse-patient-populations 2025-11-04T17:17:47+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-fosfomycin-injection-for-complicated-urinary-tract-infections 2025-11-04T17:17:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-fosfomycin-injection-for-complicated-urinary-tract-infections 2025-11-04T17:17:33+00:00 hourly 0.9 https://trial.medpath.com/news/morari-launches-fda-cleared-neurostimulation-patch-for-men-s-sexual-wellness-in-twin-cities 2025-11-04T17:17:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/morari-launches-fda-cleared-neurostimulation-patch-for-men-s-sexual-wellness-in-twin-cities 2025-11-04T17:17:28+00:00 hourly 0.9 https://trial.medpath.com/news/neok-bio-emerges-with-75m-to-develop-dual-targeting-adcs-for-cancer-treatment 2025-11-04T17:16:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neok-bio-emerges-with-75m-to-develop-dual-targeting-adcs-for-cancer-treatment 2025-11-04T17:16:57+00:00 hourly 0.9 https://trial.medpath.com/news/merck-assumes-full-control-of-mk-8690-anti-cd30-ligand-antibody-for-inflammatory-bowel-disease 2025-11-04T17:16:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-assumes-full-control-of-mk-8690-anti-cd30-ligand-antibody-for-inflammatory-bowel-disease 2025-11-04T17:16:47+00:00 hourly 0.9 https://trial.medpath.com/news/gut-microbiota-derived-metabolites-emerge-as-key-modulators-of-cancer-immunotherapy-efficacy 2025-11-04T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gut-microbiota-derived-metabolites-emerge-as-key-modulators-of-cancer-immunotherapy-efficacy 2025-11-04T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-melatonin-use-linked-to-90-higher-heart-failure-risk-in-new-study 2025-11-04T15:47:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-term-melatonin-use-linked-to-90-higher-heart-failure-risk-in-new-study 2025-11-04T15:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/rhythm-pharmaceuticals-reports-strong-q3-2025-results-with-51-3m-imcivree-revenue-and-december-fda-decision-pending 2025-11-04T13:21:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rhythm-pharmaceuticals-reports-strong-q3-2025-results-with-51-3m-imcivree-revenue-and-december-fda-decision-pending 2025-11-04T13:21:15+00:00 hourly 0.9 https://trial.medpath.com/news/merck-secures-700-million-from-blackstone-to-advance-trop2-targeting-adc-across-15-phase-3-cancer-trials 2025-11-04T13:18:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-secures-700-million-from-blackstone-to-advance-trop2-targeting-adc-across-15-phase-3-cancer-trials 2025-11-04T13:18:31+00:00 hourly 0.9 https://trial.medpath.com/news/compass-pathways-accelerates-comp360-depression-therapy-launch-by-9-12-months-following-fda-meeting 2025-11-04T13:17:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/compass-pathways-accelerates-comp360-depression-therapy-launch-by-9-12-months-following-fda-meeting 2025-11-04T13:17:59+00:00 hourly 0.9 https://trial.medpath.com/news/estrella-immunopharma-s-eb103-achieves-100-complete-response-rate-in-high-risk-b-cell-lymphoma-patients 2025-11-04T09:19:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/estrella-immunopharma-s-eb103-achieves-100-complete-response-rate-in-high-risk-b-cell-lymphoma-patients 2025-11-04T09:19:30+00:00 hourly 0.9 https://trial.medpath.com/news/valneva-s-second-generation-zika-vaccine-shows-enhanced-immune-response-in-phase-1-trial 2025-11-04T09:19:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/valneva-s-second-generation-zika-vaccine-shows-enhanced-immune-response-in-phase-1-trial 2025-11-04T09:19:27+00:00 hourly 0.9 https://trial.medpath.com/news/senti-bio-to-present-updated-senti-202-clinical-data-at-ash-2025-showcasing-logic-gate-technology-in-aml-treatment 2025-11-04T05:20:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senti-bio-to-present-updated-senti-202-clinical-data-at-ash-2025-showcasing-logic-gate-technology-in-aml-treatment 2025-11-04T05:20:56+00:00 hourly 0.9 https://trial.medpath.com/news/orsobio-s-tlc-6740-combination-therapy-achieves-51-greater-weight-loss-than-tirzepatide-alone-in-phase-1b-2a-trial 2025-11-04T01:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orsobio-s-tlc-6740-combination-therapy-achieves-51-greater-weight-loss-than-tirzepatide-alone-in-phase-1b-2a-trial 2025-11-04T01:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/incyte-showcases-first-in-class-mutant-calreticulin-antibody-inca033989-at-ash-2025-with-over-50-presentations 2025-11-04T01:23:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/incyte-showcases-first-in-class-mutant-calreticulin-antibody-inca033989-at-ash-2025-with-over-50-presentations 2025-11-04T01:23:30+00:00 hourly 0.9 https://trial.medpath.com/news/sarepta-s-essence-study-shows-mixed-results-for-duchenne-muscular-dystrophy-therapies-despite-missing-primary-endpoint 2025-11-04T01:22:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sarepta-s-essence-study-shows-mixed-results-for-duchenne-muscular-dystrophy-therapies-despite-missing-primary-endpoint 2025-11-04T01:22:50+00:00 hourly 0.9 https://trial.medpath.com/news/artiva-biotherapeutics-reports-favorable-safety-profile-for-allonk-cell-therapy-in-32-autoimmune-disease-patients 2025-11-04T01:22:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/artiva-biotherapeutics-reports-favorable-safety-profile-for-allonk-cell-therapy-in-32-autoimmune-disease-patients 2025-11-04T01:22:02+00:00 hourly 0.9 https://trial.medpath.com/news/covid-19-vaccination-reduces-long-covid-risk-by-36-in-adolescents-recover-study-shows 2025-11-04T01:21:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/covid-19-vaccination-reduces-long-covid-risk-by-36-in-adolescents-recover-study-shows 2025-11-04T01:21:57+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-files-second-federal-lawsuit-against-colorado-s-historic-drug-price-ceiling-on-enbrel 2025-11-04T01:20:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-files-second-federal-lawsuit-against-colorado-s-historic-drug-price-ceiling-on-enbrel 2025-11-04T01:20:48+00:00 hourly 0.9 https://trial.medpath.com/news/sarepta-s-duchenne-gene-therapy-fails-to-meet-primary-endpoint-in-nine-year-clinical-trial 2025-11-04T01:19:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sarepta-s-duchenne-gene-therapy-fails-to-meet-primary-endpoint-in-nine-year-clinical-trial 2025-11-04T01:19:49+00:00 hourly 0.9 https://trial.medpath.com/news/duvakitug-shows-promising-efficacy-in-first-anti-tl1a-trial-for-crohn-s-disease 2025-11-04T01:19:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/duvakitug-shows-promising-efficacy-in-first-anti-tl1a-trial-for-crohn-s-disease 2025-11-04T01:19:30+00:00 hourly 0.9 https://trial.medpath.com/news/dbv-technologies-appoints-kevin-trapp-as-chief-commercial-officer-ahead-of-viaskin-peanut-patch-bla-submission 2025-11-04T01:19:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dbv-technologies-appoints-kevin-trapp-as-chief-commercial-officer-ahead-of-viaskin-peanut-patch-bla-submission 2025-11-04T01:19:28+00:00 hourly 0.9 https://trial.medpath.com/news/transcon-pth-shows-sustained-kidney-function-improvements-in-3-year-hypoparathyroidism-study 2025-11-04T01:17:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transcon-pth-shows-sustained-kidney-function-improvements-in-3-year-hypoparathyroidism-study 2025-11-04T01:17:17+00:00 hourly 0.9 https://trial.medpath.com/news/painless-trial-launches-home-based-brain-stimulation-study-for-cancer-pain-management 2025-11-04T01:17:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/painless-trial-launches-home-based-brain-stimulation-study-for-cancer-pain-management 2025-11-04T01:17:14+00:00 hourly 0.9 https://trial.medpath.com/news/agamree-shows-superior-safety-profile-with-comparable-efficacy-to-standard-corticosteroids-in-five-year-dmd-study 2025-11-04T00:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agamree-shows-superior-safety-profile-with-comparable-efficacy-to-standard-corticosteroids-in-five-year-dmd-study 2025-11-04T00:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/star-therapeutics-reports-positive-phase-1-2-data-for-vga039-in-von-willebrand-disease-at-ash-2025 2025-11-03T21:22:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/star-therapeutics-reports-positive-phase-1-2-data-for-vga039-in-von-willebrand-disease-at-ash-2025 2025-11-03T21:22:11+00:00 hourly 0.9 https://trial.medpath.com/news/legend-biotech-to-present-comprehensive-carvykti-data-and-first-in-human-allogeneic-car-t-results-at-ash-2025 2025-11-03T21:22:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/legend-biotech-to-present-comprehensive-carvykti-data-and-first-in-human-allogeneic-car-t-results-at-ash-2025 2025-11-03T21:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/phio-pharmaceuticals-ph-762-shows-promising-results-in-phase-1b-skin-cancer-trial-with-37-5-complete-response-rate 2025-11-03T21:20:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phio-pharmaceuticals-ph-762-shows-promising-results-in-phase-1b-skin-cancer-trial-with-37-5-complete-response-rate 2025-11-03T21:20:50+00:00 hourly 0.9 https://trial.medpath.com/news/recordati-rare-diseases-presents-nine-research-studies-on-rare-hematologic-disorders-at-ash-2025 2025-11-03T21:19:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recordati-rare-diseases-presents-nine-research-studies-on-rare-hematologic-disorders-at-ash-2025 2025-11-03T21:19:39+00:00 hourly 0.9 https://trial.medpath.com/news/ryvu-therapeutics-presents-promising-clinical-data-on-romaciclib-and-dapolsertib-at-ash-2025 2025-11-03T21:18:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ryvu-therapeutics-presents-promising-clinical-data-on-romaciclib-and-dapolsertib-at-ash-2025 2025-11-03T21:18:18+00:00 hourly 0.9 https://trial.medpath.com/news/fluoguide-raises-sek-100-million-to-advance-cancer-surgery-drug-fg001-through-phase-ii-trials 2025-11-03T21:18:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fluoguide-raises-sek-100-million-to-advance-cancer-surgery-drug-fg001-through-phase-ii-trials 2025-11-03T21:18:13+00:00 hourly 0.9 https://trial.medpath.com/news/iit-madras-develops-ai-framework-pure-to-accelerate-drug-discovery-using-reinforcement-learning 2025-11-03T21:17:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iit-madras-develops-ai-framework-pure-to-accelerate-drug-discovery-using-reinforcement-learning 2025-11-03T21:17:50+00:00 hourly 0.9 https://trial.medpath.com/news/meharry-medical-college-and-novartis-launch-five-year-heart-initiative-to-combat-cardiovascular-disease-disparities 2025-11-03T17:38:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/meharry-medical-college-and-novartis-launch-five-year-heart-initiative-to-combat-cardiovascular-disease-disparities 2025-11-03T17:38:14+00:00 hourly 0.9 https://trial.medpath.com/news/nautilus-biotechnology-achieves-milestone-with-first-external-field-evaluation-unit-for-alzheimer-s-research 2025-11-03T17:35:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nautilus-biotechnology-achieves-milestone-with-first-external-field-evaluation-unit-for-alzheimer-s-research 2025-11-03T17:35:26+00:00 hourly 0.9 https://trial.medpath.com/news/tscan-therapeutics-secures-fda-agreement-for-tsc-101-pivotal-trial-implements-strategic-restructuring 2025-11-03T17:34:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tscan-therapeutics-secures-fda-agreement-for-tsc-101-pivotal-trial-implements-strategic-restructuring 2025-11-03T17:34:13+00:00 hourly 0.9 https://trial.medpath.com/news/altamira-therapeutics-expands-xphore-platform-with-successful-dna-delivery-technology 2025-11-03T17:33:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/altamira-therapeutics-expands-xphore-platform-with-successful-dna-delivery-technology 2025-11-03T17:33:14+00:00 hourly 0.9 https://trial.medpath.com/news/abcuro-s-ulviprubart-shows-promising-interim-results-in-rare-blood-cancer-t-lgll 2025-11-03T17:32:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abcuro-s-ulviprubart-shows-promising-interim-results-in-rare-blood-cancer-t-lgll 2025-11-03T17:32:34+00:00 hourly 0.9 https://trial.medpath.com/news/capricor-publishes-peer-reviewed-study-validating-deramiocel-s-anti-fibrotic-mechanism-for-duchenne-muscular-dystrophy 2025-11-03T17:31:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/capricor-publishes-peer-reviewed-study-validating-deramiocel-s-anti-fibrotic-mechanism-for-duchenne-muscular-dystrophy 2025-11-03T17:31:28+00:00 hourly 0.9 https://trial.medpath.com/news/bioinvent-reports-promising-safety-and-efficacy-data-for-triple-combination-therapy-in-relapsed-refractory-non-hodgkin-s-lymphoma 2025-11-03T17:31:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioinvent-reports-promising-safety-and-efficacy-data-for-triple-combination-therapy-in-relapsed-refractory-non-hodgkin-s-lymphoma 2025-11-03T17:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/march-biosciences-to-present-interim-phase-2-data-for-first-in-class-cd5-targeted-car-t-therapy-at-ash-2025 2025-11-03T17:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/march-biosciences-to-present-interim-phase-2-data-for-first-in-class-cd5-targeted-car-t-therapy-at-ash-2025 2025-11-03T17:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/cullinan-therapeutics-reports-promising-30-response-rate-for-cln-049-t-cell-engager-in-relapsed-aml-patients 2025-11-03T17:29:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cullinan-therapeutics-reports-promising-30-response-rate-for-cln-049-t-cell-engager-in-relapsed-aml-patients 2025-11-03T17:29:03+00:00 hourly 0.9 https://trial.medpath.com/news/kimberly-clark-acquires-kenvue-for-48-7-billion-creating-consumer-health-giant 2025-11-03T17:28:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kimberly-clark-acquires-kenvue-for-48-7-billion-creating-consumer-health-giant 2025-11-03T17:28:53+00:00 hourly 0.9 https://trial.medpath.com/news/genmab-presents-pivotal-phase-3-data-for-epcoritamab-at-ash-2025-expanding-treatment-options-across-b-cell-malignancies 2025-11-03T17:27:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genmab-presents-pivotal-phase-3-data-for-epcoritamab-at-ash-2025-expanding-treatment-options-across-b-cell-malignancies 2025-11-03T17:27:45+00:00 hourly 0.9 https://trial.medpath.com/news/benitec-biopharma-s-bb-301-gene-therapy-receives-fda-fast-track-designation-for-opmd-treatment 2025-11-03T17:27:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/benitec-biopharma-s-bb-301-gene-therapy-receives-fda-fast-track-designation-for-opmd-treatment 2025-11-03T17:27:42+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-doses-first-patient-in-phase-1-2-trial-of-novel-mrna-t-cell-engager-for-multiple-myeloma 2025-11-03T17:27:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-doses-first-patient-in-phase-1-2-trial-of-novel-mrna-t-cell-engager-for-multiple-myeloma 2025-11-03T17:27:15+00:00 hourly 0.9 https://trial.medpath.com/news/akums-drugs-secures-20-year-patent-for-dual-release-ppi-technology-targeting-gerd-treatment 2025-11-03T17:27:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akums-drugs-secures-20-year-patent-for-dual-release-ppi-technology-targeting-gerd-treatment 2025-11-03T17:27:02+00:00 hourly 0.9 https://trial.medpath.com/news/orna-therapeutics-to-present-in-vivo-car-t-data-at-ash-2025-plans-clinical-trial-application-for-cd19-program 2025-11-03T17:26:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orna-therapeutics-to-present-in-vivo-car-t-data-at-ash-2025-plans-clinical-trial-application-for-cd19-program 2025-11-03T17:26:51+00:00 hourly 0.9 https://trial.medpath.com/news/icecure-s-cryoablation-combined-with-radiation-therapy-achieves-74-five-year-survival-in-stage-i-lung-cancer 2025-11-03T17:26:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/icecure-s-cryoablation-combined-with-radiation-therapy-achieves-74-five-year-survival-in-stage-i-lung-cancer 2025-11-03T17:26:40+00:00 hourly 0.9 https://trial.medpath.com/news/phio-pharmaceuticals-reports-promising-phase-1b-results-for-ph-762-in-cutaneous-squamous-cell-carcinoma 2025-11-03T17:26:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phio-pharmaceuticals-reports-promising-phase-1b-results-for-ph-762-in-cutaneous-squamous-cell-carcinoma 2025-11-03T17:26:25+00:00 hourly 0.9 https://trial.medpath.com/news/evaxion-unveils-ai-designed-cancer-vaccine-evx-04-targeting-acute-myeloid-leukemia 2025-11-03T17:25:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evaxion-unveils-ai-designed-cancer-vaccine-evx-04-targeting-acute-myeloid-leukemia 2025-11-03T17:25:22+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-spatial-biology-platforms-advance-predictive-biomarker-discovery-in-cancer-immunotherapy 2025-11-03T17:25:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-powered-spatial-biology-platforms-advance-predictive-biomarker-discovery-in-cancer-immunotherapy 2025-11-03T17:25:17+00:00 hourly 0.9 https://trial.medpath.com/news/crescent-biopharma-advances-pd-1-x-vegf-bispecific-antibody-cr-001-toward-phase-1-trial 2025-11-03T17:25:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crescent-biopharma-advances-pd-1-x-vegf-bispecific-antibody-cr-001-toward-phase-1-trial 2025-11-03T17:25:15+00:00 hourly 0.9 https://trial.medpath.com/news/ileukon-receives-fda-clearance-for-phase-ii-trial-of-mrna-based-il-2-therapy-ilkn421h-in-advanced-nsclc 2025-11-03T17:25:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ileukon-receives-fda-clearance-for-phase-ii-trial-of-mrna-based-il-2-therapy-ilkn421h-in-advanced-nsclc 2025-11-03T17:25:02+00:00 hourly 0.9 https://trial.medpath.com/news/opus-genetics-gene-therapy-shows-promise-in-restoring-vision-for-inherited-blindness 2025-11-03T17:24:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/opus-genetics-gene-therapy-shows-promise-in-restoring-vision-for-inherited-blindness 2025-11-03T17:24:59+00:00 hourly 0.9 https://trial.medpath.com/news/life-biosciences-appoints-veteran-biotech-leader-david-guyer-to-board-as-company-prepares-for-first-human-trials 2025-11-03T17:23:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/life-biosciences-appoints-veteran-biotech-leader-david-guyer-to-board-as-company-prepares-for-first-human-trials 2025-11-03T17:23:59+00:00 hourly 0.9 https://trial.medpath.com/news/roche-showcases-comprehensive-hematology-pipeline-at-ash-2025-with-46-abstracts-spanning-blood-disorders 2025-11-03T17:23:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-showcases-comprehensive-hematology-pipeline-at-ash-2025-with-46-abstracts-spanning-blood-disorders 2025-11-03T17:23:52+00:00 hourly 0.9 https://trial.medpath.com/news/apnimed-s-sulthiame-shows-promise-in-phase-2-trial-for-obstructive-sleep-apnea-results-published-in-the-lancet 2025-11-03T17:22:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apnimed-s-sulthiame-shows-promise-in-phase-2-trial-for-obstructive-sleep-apnea-results-published-in-the-lancet 2025-11-03T17:22:39+00:00 hourly 0.9 https://trial.medpath.com/news/sumitomo-pharma-reports-promising-clinical-data-for-enzomenib-and-nuvisertib-ahead-of-ash-2025 2025-11-03T17:22:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sumitomo-pharma-reports-promising-clinical-data-for-enzomenib-and-nuvisertib-ahead-of-ash-2025 2025-11-03T17:22:18+00:00 hourly 0.9 https://trial.medpath.com/news/theralase-s-rutherrin-shows-100-fold-cancer-cell-kill-enhancement-in-preclinical-studies 2025-11-03T17:20:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/theralase-s-rutherrin-shows-100-fold-cancer-cell-kill-enhancement-in-preclinical-studies 2025-11-03T17:20:21+00:00 hourly 0.9 https://trial.medpath.com/news/igc-pharma-expands-ai-powered-drug-discovery-platform-for-alzheimer-s-disease-development 2025-11-03T17:19:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/igc-pharma-expands-ai-powered-drug-discovery-platform-for-alzheimer-s-disease-development 2025-11-03T17:19:48+00:00 hourly 0.9 https://trial.medpath.com/news/vorasidenib-demonstrates-sustained-long-term-efficacy-in-idh-mutant-grade-2-glioma 2025-11-03T17:19:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vorasidenib-demonstrates-sustained-long-term-efficacy-in-idh-mutant-grade-2-glioma 2025-11-03T17:19:45+00:00 hourly 0.9 https://trial.medpath.com/news/kidney-week-2025-showcases-breakthrough-therapies-across-nephrology-with-eight-major-trial-updates 2025-11-03T17:19:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kidney-week-2025-showcases-breakthrough-therapies-across-nephrology-with-eight-major-trial-updates 2025-11-03T17:19:17+00:00 hourly 0.9 https://trial.medpath.com/news/iovance-reports-promising-26-response-rate-for-lifileucel-til-therapy-in-advanced-nsclc 2025-11-03T17:19:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iovance-reports-promising-26-response-rate-for-lifileucel-til-therapy-in-advanced-nsclc 2025-11-03T17:19:15+00:00 hourly 0.9 https://trial.medpath.com/news/doseme-acquires-firstline-to-create-integrated-clinical-decision-support-platform-for-antimicrobial-stewardship 2025-11-03T17:19:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/doseme-acquires-firstline-to-create-integrated-clinical-decision-support-platform-for-antimicrobial-stewardship 2025-11-03T17:19:10+00:00 hourly 0.9 https://trial.medpath.com/news/femasys-secures-fda-approval-to-advance-final-phase-of-fembloc-pivotal-trial-for-non-surgical-permanent-birth-control 2025-11-03T17:17:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/femasys-secures-fda-approval-to-advance-final-phase-of-fembloc-pivotal-trial-for-non-surgical-permanent-birth-control 2025-11-03T17:17:44+00:00 hourly 0.9 https://trial.medpath.com/news/united-therapeutics-achieves-first-clinical-xenotransplantation-with-genetically-modified-pig-kidney-in-expand-trial 2025-11-03T17:17:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/united-therapeutics-achieves-first-clinical-xenotransplantation-with-genetically-modified-pig-kidney-in-expand-trial 2025-11-03T17:17:39+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-s-qdenga-dengue-vaccine-demonstrates-sustained-seven-year-protection-in-phase-3-trial 2025-11-03T17:17:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/takeda-s-qdenga-dengue-vaccine-demonstrates-sustained-seven-year-protection-in-phase-3-trial 2025-11-03T17:17:03+00:00 hourly 0.9 https://trial.medpath.com/news/sanyou-bio-and-shanghai-zj-bio-tech-form-strategic-partnership-to-accelerate-biologics-development-through-ai-and-automation 2025-11-03T17:16:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanyou-bio-and-shanghai-zj-bio-tech-form-strategic-partnership-to-accelerate-biologics-development-through-ai-and-automation 2025-11-03T17:16:49+00:00 hourly 0.9 https://trial.medpath.com/news/nuclera-partners-with-solve-scientific-to-expand-eprotein-discovery-platform-access-in-australia-and-new-zealand 2025-11-03T13:19:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuclera-partners-with-solve-scientific-to-expand-eprotein-discovery-platform-access-in-australia-and-new-zealand 2025-11-03T13:19:44+00:00 hourly 0.9 https://trial.medpath.com/news/boost-pharma-secures-eur3-1-million-to-advance-stem-cell-therapy-for-osteogenesis-imperfecta 2025-11-03T13:19:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boost-pharma-secures-eur3-1-million-to-advance-stem-cell-therapy-for-osteogenesis-imperfecta 2025-11-03T13:19:34+00:00 hourly 0.9 https://trial.medpath.com/news/aavantgarde-secures-141-million-series-b-to-advance-gene-therapies-for-stargardt-disease-and-usher-1b-syndrome 2025-11-03T13:17:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aavantgarde-secures-141-million-series-b-to-advance-gene-therapies-for-stargardt-disease-and-usher-1b-syndrome 2025-11-03T13:17:45+00:00 hourly 0.9 https://trial.medpath.com/news/roche-partners-with-manifold-bio-in-2b-ai-driven-deal-to-overcome-blood-brain-barrier-for-neurological-diseases 2025-11-03T13:17:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-partners-with-manifold-bio-in-2b-ai-driven-deal-to-overcome-blood-brain-barrier-for-neurological-diseases 2025-11-03T13:17:24+00:00 hourly 0.9 https://trial.medpath.com/news/bharat-biotech-launches-nucelion-crdmo-to-advance-cell-and-gene-therapy-manufacturing-in-india 2025-11-03T13:16:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bharat-biotech-launches-nucelion-crdmo-to-advance-cell-and-gene-therapy-manufacturing-in-india 2025-11-03T13:16:13+00:00 hourly 0.9 https://trial.medpath.com/news/stcube-reports-promising-phase-1b-results-for-btn1a1-targeted-therapy-in-metastatic-colorectal-cancer 2025-11-03T09:17:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stcube-reports-promising-phase-1b-results-for-btn1a1-targeted-therapy-in-metastatic-colorectal-cancer 2025-11-03T09:17:36+00:00 hourly 0.9 https://trial.medpath.com/news/south-korea-approves-first-epilepsy-drug-under-new-fast-track-review-process 2025-11-03T09:17:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/south-korea-approves-first-epilepsy-drug-under-new-fast-track-review-process 2025-11-03T09:17:15+00:00 hourly 0.9 https://trial.medpath.com/news/ensurge-and-corning-partner-to-develop-ultra-high-energy-density-solid-state-microbatteries-for-medical-applications 2025-11-03T09:17:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ensurge-and-corning-partner-to-develop-ultra-high-energy-density-solid-state-microbatteries-for-medical-applications 2025-11-03T09:17:12+00:00 hourly 0.9 https://trial.medpath.com/news/gc-biopharma-s-barythrax-becomes-world-s-first-recombinant-anthrax-vaccine-to-show-protective-immunity-in-phase-2-trial 2025-11-03T09:16:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gc-biopharma-s-barythrax-becomes-world-s-first-recombinant-anthrax-vaccine-to-show-protective-immunity-in-phase-2-trial 2025-11-03T09:16:49+00:00 hourly 0.9 https://trial.medpath.com/news/arctic-therapeutics-receives-ema-approval-for-phase-iia-study-of-at-001-in-alzheimer-s-disease 2025-11-03T09:16:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arctic-therapeutics-receives-ema-approval-for-phase-iia-study-of-at-001-in-alzheimer-s-disease 2025-11-03T09:16:02+00:00 hourly 0.9 https://trial.medpath.com/news/tuhura-biosciences-unveils-delta-opioid-receptor-as-novel-target-to-overcome-cancer-immunotherapy-resistance 2025-11-03T06:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tuhura-biosciences-unveils-delta-opioid-receptor-as-novel-target-to-overcome-cancer-immunotherapy-resistance 2025-11-03T06:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-establishes-new-holding-company-to-expand-beyond-biosimilars-into-next-generation-biotechnology 2025-11-03T05:17:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samsung-establishes-new-holding-company-to-expand-beyond-biosimilars-into-next-generation-biotechnology 2025-11-03T05:17:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-complete-response-letter-for-alvotech-s-golimumab-biosimilar-avt05 2025-11-03T01:17:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-complete-response-letter-for-alvotech-s-golimumab-biosimilar-avt05 2025-11-03T01:17:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-drug-center-chief-george-tidmarsh-resigns-amid-ethics-probe-and-industry-lawsuit 2025-11-03T01:16:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-drug-center-chief-george-tidmarsh-resigns-amid-ethics-probe-and-industry-lawsuit 2025-11-03T01:16:47+00:00 hourly 0.9 https://trial.medpath.com/news/gore-viabahn-fortegra-venous-stent-achieves-83-4-primary-patency-in-deep-venous-obstruction-trial 2025-11-03T01:16:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gore-viabahn-fortegra-venous-stent-achieves-83-4-primary-patency-in-deep-venous-obstruction-trial 2025-11-03T01:16:16+00:00 hourly 0.9 https://trial.medpath.com/news/sk-biopharmaceuticals-partners-with-interon-to-develop-first-in-class-autism-treatment-using-neuroimmune-approach 2025-11-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sk-biopharmaceuticals-partners-with-interon-to-develop-first-in-class-autism-treatment-using-neuroimmune-approach 2025-11-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/aura-biosciences-bel-sar-shows-promise-in-non-muscle-invasive-bladder-cancer-phase-1-study 2025-11-02T21:21:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aura-biosciences-bel-sar-shows-promise-in-non-muscle-invasive-bladder-cancer-phase-1-study 2025-11-02T21:21:06+00:00 hourly 0.9 https://trial.medpath.com/news/fate-therapeutics-reports-promising-phase-1-data-for-off-the-shelf-car-t-therapy-in-lupus 2025-11-02T17:17:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fate-therapeutics-reports-promising-phase-1-data-for-off-the-shelf-car-t-therapy-in-lupus 2025-11-02T17:17:57+00:00 hourly 0.9 https://trial.medpath.com/news/henlius-biotech-achieves-breakthrough-in-gastric-cancer-immunotherapy-with-serplulimab-phase-3-success 2025-11-02T17:17:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/henlius-biotech-achieves-breakthrough-in-gastric-cancer-immunotherapy-with-serplulimab-phase-3-success 2025-11-02T17:17:55+00:00 hourly 0.9 https://trial.medpath.com/news/nigeria-secures-eur10-2-million-eu-partnership-to-boost-local-pharmaceutical-manufacturing 2025-11-02T17:16:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nigeria-secures-eur10-2-million-eu-partnership-to-boost-local-pharmaceutical-manufacturing 2025-11-02T17:16:49+00:00 hourly 0.9 https://trial.medpath.com/news/oncohost-advances-plasma-proteomics-for-nsclc-immunotherapy-monitoring-and-prediction 2025-11-02T17:16:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncohost-advances-plasma-proteomics-for-nsclc-immunotherapy-monitoring-and-prediction 2025-11-02T17:16:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-s-q-collar-approval-under-fire-as-internal-reviewers-warned-of-flawed-evidence 2025-11-02T17:16:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-s-q-collar-approval-under-fire-as-internal-reviewers-warned-of-flawed-evidence 2025-11-02T17:16:38+00:00 hourly 0.9 https://trial.medpath.com/news/pulsenmore-receives-fda-approval-for-first-home-use-ultrasound-device-for-pregnant-women 2025-11-02T17:15:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pulsenmore-receives-fda-approval-for-first-home-use-ultrasound-device-for-pregnant-women 2025-11-02T17:15:58+00:00 hourly 0.9 https://trial.medpath.com/news/upadacitinib-30mg-demonstrates-superior-efficacy-among-jak-inhibitors-for-atopic-dermatitis-while-safety-analysis-reveals-new-infection-risks 2025-11-02T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/upadacitinib-30mg-demonstrates-superior-efficacy-among-jak-inhibitors-for-atopic-dermatitis-while-safety-analysis-reveals-new-infection-risks 2025-11-02T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/royal-united-hospitals-bath-launches-clinical-trial-testing-repurposed-drugs-for-lacunar-stroke-prevention 2025-11-02T13:17:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/royal-united-hospitals-bath-launches-clinical-trial-testing-repurposed-drugs-for-lacunar-stroke-prevention 2025-11-02T13:17:48+00:00 hourly 0.9 https://trial.medpath.com/news/statins-show-promise-in-protecting-cancer-patients-from-chemotherapy-related-cognitive-decline 2025-11-02T09:17:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/statins-show-promise-in-protecting-cancer-patients-from-chemotherapy-related-cognitive-decline 2025-11-02T09:17:32+00:00 hourly 0.9 https://trial.medpath.com/news/invex-therapeutics-advances-presendin-phase-iii-trial-for-idiopathic-intracranial-hypertension-with-fda-guidance 2025-11-02T05:17:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/invex-therapeutics-advances-presendin-phase-iii-trial-for-idiopathic-intracranial-hypertension-with-fda-guidance 2025-11-02T05:17:26+00:00 hourly 0.9 https://trial.medpath.com/news/rituximab-shows-higher-cmv-reactivation-risk-than-obinutuzumab-in-follicular-lymphoma-treatment 2025-11-02T01:17:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rituximab-shows-higher-cmv-reactivation-risk-than-obinutuzumab-in-follicular-lymphoma-treatment 2025-11-02T01:17:27+00:00 hourly 0.9 https://trial.medpath.com/news/bassett-cancer-institute-launches-alpha-dart-clinical-trial-for-inoperable-pancreatic-cancer 2025-11-02T01:16:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bassett-cancer-institute-launches-alpha-dart-clinical-trial-for-inoperable-pancreatic-cancer 2025-11-02T01:16:18+00:00 hourly 0.9 https://trial.medpath.com/news/uk-government-launches-ps650000-obesity-study-targeting-scotland-s-most-deprived-communities 2025-11-01T21:17:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-government-launches-ps650000-obesity-study-targeting-scotland-s-most-deprived-communities 2025-11-01T21:17:50+00:00 hourly 0.9 https://trial.medpath.com/news/icmr-seeks-industry-partners-to-develop-indigenous-monoclonal-antibodies-against-deadly-nipah-virus 2025-11-01T17:21:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/icmr-seeks-industry-partners-to-develop-indigenous-monoclonal-antibodies-against-deadly-nipah-virus 2025-11-01T17:21:36+00:00 hourly 0.9 https://trial.medpath.com/news/galapagos-appoints-new-board-directors-to-accelerate-business-development-strategy 2025-11-01T17:19:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galapagos-appoints-new-board-directors-to-accelerate-business-development-strategy 2025-11-01T17:19:17+00:00 hourly 0.9 https://trial.medpath.com/news/pharmadrug-acquires-40-stake-in-canurta-to-advance-botanical-therapeutics-for-als-and-neurodegenerative-diseases 2025-11-01T17:18:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmadrug-acquires-40-stake-in-canurta-to-advance-botanical-therapeutics-for-als-and-neurodegenerative-diseases 2025-11-01T17:18:23+00:00 hourly 0.9 https://trial.medpath.com/news/stoke-therapeutics-advances-phase-3-emperor-trial-for-dravet-syndrome-treatment-with-supporting-natural-history-data 2025-11-01T17:17:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stoke-therapeutics-advances-phase-3-emperor-trial-for-dravet-syndrome-treatment-with-supporting-natural-history-data 2025-11-01T17:17:54+00:00 hourly 0.9 https://trial.medpath.com/news/cybin-closes-175-million-financing-to-advance-phase-3-psychedelic-depression-treatment 2025-11-01T17:17:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cybin-closes-175-million-financing-to-advance-phase-3-psychedelic-depression-treatment 2025-11-01T17:17:46+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-secures-early-antitrust-clearance-for-7-3-billion-metsera-acquisition-amid-novo-nordisk-s-competing-bid 2025-11-01T01:23:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-secures-early-antitrust-clearance-for-7-3-billion-metsera-acquisition-amid-novo-nordisk-s-competing-bid 2025-11-01T01:23:38+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-startup-secures-30-million-to-research-gene-edited-babies-despite-scientific-opposition 2025-11-01T01:22:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotech-startup-secures-30-million-to-research-gene-edited-babies-despite-scientific-opposition 2025-11-01T01:22:22+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-pursues-metsera-acquisition-with-amended-proposal-to-strengthen-obesity-pipeline 2025-11-01T01:19:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-pursues-metsera-acquisition-with-amended-proposal-to-strengthen-obesity-pipeline 2025-11-01T01:19:29+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-form-483-to-hetero-labs-following-inspection-revealing-severe-gmp-violations-at-undisclosed-warehouse 2025-11-01T01:19:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-form-483-to-hetero-labs-following-inspection-revealing-severe-gmp-violations-at-undisclosed-warehouse 2025-11-01T01:19:15+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-submits-fda-application-for-stelara-in-pediatric-ulcerative-colitis 2025-11-01T01:16:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-submits-fda-application-for-stelara-in-pediatric-ulcerative-colitis 2025-11-01T01:16:42+00:00 hourly 0.9 https://trial.medpath.com/news/fda-takes-enforcement-action-against-unapproved-pediatric-fluoride-supplements-citing-gut-microbiome-concerns 2025-10-31T21:23:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-takes-enforcement-action-against-unapproved-pediatric-fluoride-supplements-citing-gut-microbiome-concerns 2025-10-31T21:23:28+00:00 hourly 0.9 https://trial.medpath.com/news/hrsa-approves-eight-drug-companies-for-340b-rebate-model-pilot-program-starting-january-2025 2025-10-31T21:23:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hrsa-approves-eight-drug-companies-for-340b-rebate-model-pilot-program-starting-january-2025 2025-10-31T21:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/oral-salmonella-paratyphi-a-vaccine-demonstrates-73-efficacy-in-first-human-challenge-trial 2025-10-31T21:20:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oral-salmonella-paratyphi-a-vaccine-demonstrates-73-efficacy-in-first-human-challenge-trial 2025-10-31T21:20:10+00:00 hourly 0.9 https://trial.medpath.com/news/sensei-biotherapeutics-abandons-lead-cancer-drug-solnerstotug-despite-promising-phase-i-results 2025-10-31T21:19:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sensei-biotherapeutics-abandons-lead-cancer-drug-solnerstotug-despite-promising-phase-i-results 2025-10-31T21:19:15+00:00 hourly 0.9 https://trial.medpath.com/news/intensity-therapeutics-stock-surges-400-following-promising-phase-i-ii-data-for-int230-6-in-solid-tumors 2025-10-31T17:29:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intensity-therapeutics-stock-surges-400-following-promising-phase-i-ii-data-for-int230-6-in-solid-tumors 2025-10-31T17:29:09+00:00 hourly 0.9 https://trial.medpath.com/news/imodern-trial-shows-immediate-vs-delayed-heart-attack-treatment-equally-safe-published-in-nejm 2025-10-31T17:26:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imodern-trial-shows-immediate-vs-delayed-heart-attack-treatment-equally-safe-published-in-nejm 2025-10-31T17:26:43+00:00 hourly 0.9 https://trial.medpath.com/news/alps-group-completes-1-6-billion-spac-merger-lists-on-nasdaq-to-advance-precision-medicine-platform 2025-10-31T17:24:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alps-group-completes-1-6-billion-spac-merger-lists-on-nasdaq-to-advance-precision-medicine-platform 2025-10-31T17:24:57+00:00 hourly 0.9 https://trial.medpath.com/news/biostem-s-bioretain-allograft-shows-71-higher-healing-rate-in-diabetic-foot-ulcer-trial 2025-10-31T17:21:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biostem-s-bioretain-allograft-shows-71-higher-healing-rate-in-diabetic-foot-ulcer-trial 2025-10-31T17:21:43+00:00 hourly 0.9 https://trial.medpath.com/news/biocardia-advances-phase-3-cardiamp-hf-ii-trial-with-first-patient-enrollment-at-university-of-wisconsin 2025-10-31T17:21:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocardia-advances-phase-3-cardiamp-hf-ii-trial-with-first-patient-enrollment-at-university-of-wisconsin 2025-10-31T17:21:29+00:00 hourly 0.9 https://trial.medpath.com/news/nclat-rules-competition-commission-cannot-investigate-patent-protected-drug-pricing-disputes 2025-10-31T17:21:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nclat-rules-competition-commission-cannot-investigate-patent-protected-drug-pricing-disputes 2025-10-31T17:21:01+00:00 hourly 0.9 https://trial.medpath.com/news/libtayo-gains-widespread-provincial-reimbursement-across-canada-for-advanced-nsclc-and-basal-cell-carcinoma 2025-10-31T17:19:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/libtayo-gains-widespread-provincial-reimbursement-across-canada-for-advanced-nsclc-and-basal-cell-carcinoma 2025-10-31T17:19:24+00:00 hourly 0.9 https://trial.medpath.com/news/stem-cell-therapy-shows-78-fracture-reduction-in-children-with-osteogenesis-imperfecta 2025-10-31T17:19:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stem-cell-therapy-shows-78-fracture-reduction-in-children-with-osteogenesis-imperfecta 2025-10-31T17:19:06+00:00 hourly 0.9 https://trial.medpath.com/news/lilly-discontinues-p2x7-inhibitor-ly3857210-for-chronic-pain-after-phase-ii-failure 2025-10-31T17:17:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lilly-discontinues-p2x7-inhibitor-ly3857210-for-chronic-pain-after-phase-ii-failure 2025-10-31T17:17:27+00:00 hourly 0.9 https://trial.medpath.com/news/hemlibra-demonstrates-exercise-related-bleeding-prevention-in-hemophilia-a-as-pfizer-reports-positive-phase-iii-baisis-results 2025-10-31T17:16:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hemlibra-demonstrates-exercise-related-bleeding-prevention-in-hemophilia-a-as-pfizer-reports-positive-phase-iii-baisis-results 2025-10-31T17:16:32+00:00 hourly 0.9 https://trial.medpath.com/news/federal-cancer-trials-fill-critical-gaps-left-by-industry-funding-asco-analysis-reveals 2025-10-31T17:15:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-cancer-trials-fill-critical-gaps-left-by-industry-funding-asco-analysis-reveals 2025-10-31T17:15:55+00:00 hourly 0.9 https://trial.medpath.com/news/q4-2025-biotech-catalyst-monitor-identifies-20-key-pipeline-events-including-cytokinetics-aficamten-and-gsk-s-depemokimab 2025-10-31T13:23:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/q4-2025-biotech-catalyst-monitor-identifies-20-key-pipeline-events-including-cytokinetics-aficamten-and-gsk-s-depemokimab 2025-10-31T13:23:58+00:00 hourly 0.9 https://trial.medpath.com/news/vesper-bio-s-ves001-shows-95-increase-in-progranulin-levels-in-phase-ib-iia-trial-for-frontotemporal-degeneration 2025-10-31T13:23:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vesper-bio-s-ves001-shows-95-increase-in-progranulin-levels-in-phase-ib-iia-trial-for-frontotemporal-degeneration 2025-10-31T13:23:46+00:00 hourly 0.9 https://trial.medpath.com/news/aspen-pharmacare-secures-eur25-million-settlement-in-mrna-manufacturing-dispute 2025-10-31T13:22:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aspen-pharmacare-secures-eur25-million-settlement-in-mrna-manufacturing-dispute 2025-10-31T13:22:47+00:00 hourly 0.9 https://trial.medpath.com/news/b7-h3-targeted-adc-hs-20093-demonstrates-promising-efficacy-in-relapsed-refractory-sarcomas-receives-fda-breakthrough-designation 2025-10-31T13:21:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/b7-h3-targeted-adc-hs-20093-demonstrates-promising-efficacy-in-relapsed-refractory-sarcomas-receives-fda-breakthrough-designation 2025-10-31T13:21:57+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-gefurulimab-meets-phase-iii-endpoints-in-myasthenia-gravis-but-lags-behind-competitor-therapies 2025-10-31T13:21:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-s-gefurulimab-meets-phase-iii-endpoints-in-myasthenia-gravis-but-lags-behind-competitor-therapies 2025-10-31T13:21:55+00:00 hourly 0.9